var title_f27_56_28544="Intraosseous blood supply";
var content_f27_56_28544=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Intraosseous blood supply of the fifth metatarsal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 222px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The three principal arteries are: the metaphyseal arteries, periosteal arteries, and nutrient artery. High rates of nonunion among acute and stress fractures of the proximal diaphysis may be attributable to its relatively poor blood supply via the nutrient artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_56_28544=[""].join("\n");
var outline_f27_56_28544=null;
var title_f27_56_28545="CT of hepatosplenic candidiasis";
var content_f27_56_28545=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatosplenic candidiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple \"punched-out\" lesions in the liver, spleen, and kidneys in a patient with chronic disseminated candidiasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rolston, K, Bodey, GP. Infections in Patients With Cancer. In: Cancer Medicine, 8th ed, Hong, WK, Bast, RC Jr, Hait, W, et al. (Eds), People's Medical Publishing House, 2010. Copyright &copy; 2010 PMPH-USA, Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_56_28545=[""].join("\n");
var outline_f27_56_28545=null;
var title_f27_56_28546="Patient information: Seizures (The Basics)";
var content_f27_56_28546=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/0/18434\">",
"         Patient information: EEG (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/5/30802\">",
"         Patient information: Epilepsy and pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/40/43650\">",
"         Patient information: Epilepsy in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/54/38754\">",
"         Patient information: Epilepsy in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?38/35/39473\">",
"         Patient information: Febrile seizures (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/27/34229\">",
"         Patient information: Seizures in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/26/419\">",
"         Patient information: Seizures in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/5/19540\">",
"         Patient information: Treatment of seizures in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Seizures (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/seizures-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H550777130\">",
"      <span class=\"h1\">",
"       What are seizures?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Seizures are waves of abnormal electrical activity in the brain. Seizures can make you pass out, or move or behave strangely. Most seizures last only a few seconds or minutes.",
"     </p>",
"     <p>",
"      Epilepsy is a condition that causes people to have repeated seizures. But not everyone who has had a seizure has epilepsy. Problems such as low blood sugar or infection can also cause seizures. Other problems such as anxiety or fainting spells can cause events that look like seizures.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H550777137\">",
"      <span class=\"h1\">",
"       What are the symptoms of a seizure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are different kinds of seizures. Each causes a different set of symptoms.",
"     </p>",
"     <p>",
"      People who have &ldquo;tonic clonic&rdquo; or &ldquo;grand mal&rdquo; seizures often get stiff and then have jerking movements. People who have other types of seizures have less dramatic changes. For instance, some people have shaking movements in just one arm or in a part of their face. Other people suddenly stop responding and stare for a few seconds.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H550777144\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse if I have a seizure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have never had a seizure before and you have one, you (or whoever is with you) should call 9-1-1 for an ambulance. Having a seizure can be a sign that something is wrong with your brain.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H550777151\">",
"      <span class=\"h1\">",
"       How are seizures treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The right treatment for seizures depends on what is causing them. If you have seizures because of an infection, you will probably need treatments to get rid of the infection. On the other hand, if you have repeated seizures because of epilepsy, you will probably need anti-seizure medicines.",
"     </p>",
"     <p>",
"      People sometimes need to try different medicines before they find a treatment that works well. Seizures can be hard to control. But if you work with your doctor, chances are good that you will find a treatment that works.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H550777158\">",
"      <span class=\"h1\">",
"       Do anti-seizure medicines cause side effects?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Anti-seizure medicines can cause side effects. They can make you feel tired or clumsy, or cause other problems. If you are bothered by side effects, tell your doctor about it. He or she can work with you to find the medicine or dose that causes the fewest problems. Most of the side effects from these medicines are mild, but there are two rare side effects that are very serious:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Anti-seizure medicines can increase the risk of becoming suicidal (wanting to kill yourself).",
"        </strong>",
"        Speak to your doctor or nurse right away if you start to feel depressed or have thoughts of harming yourself.",
"       </li>",
"       <li>",
"        <strong>",
"         Anti-seizure medicines can cause a rare but serious skin rash.",
"        </strong>",
"        Speak to your doctor or nurse right away if you notice a new rash while taking an anti-seizure medicine.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H550777165\">",
"      <span class=\"h1\">",
"       What if anti-seizure medicines do not work for me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you keep having seizures even after trying different medicines, you might have other options. Some people have surgery to remove the part of their brain that is causing seizures. Others get a device put in their chest that helps control seizures",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H550777172\">",
"      <span class=\"h1\">",
"       How can I reduce my chances of having more seizures?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Take your medicines exactly as directed &mdash; at the right times, and at the right doses.",
"       </li>",
"       <li>",
"        Tell your doctor about any side effects you have. That way the two of you can find the best medicine for you.",
"       </li>",
"       <li>",
"        Be careful not to let your prescription run out. (Stopping anti-seizure medicine suddenly can put you at risk of seizure.)",
"       </li>",
"       <li>",
"        While on anti-seizure medicines, check with your doctor before starting any new medicines. Anti-seizure medicines can interact with prescription and non-prescription medicines, and with herbal drugs. Mixing them can increase side effects or make them not work as well.",
"       </li>",
"       <li>",
"        Avoid alcohol. Alcohol can increase the risk of seizures, affect the way seizure medicines work, and increase side effects from seizure medicines.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H550777179\">",
"      <span class=\"h1\">",
"       What should my family members do if they see me having a seizure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ask your doctor what your family members should do. Some people will have seizures from time to time, and they may not need to see a doctor every time. But if you have a seizure that lasts longer than 5 minutes or if you do not wake up after a seizure, your family members should call 9-1-1 for an ambulance.",
"     </p>",
"     <p>",
"      Your family members should",
"      <strong>",
"       not",
"      </strong>",
"      try to put anything in your mouth while you are having a seizure. But they should make sure you do not bang against any hard surfaces.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H550777186\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you take anti-seizure medicines, speak to your doctor or nurse before you start trying to get pregnant. Some anti-seizure medicines can hurt an unborn baby. You may need to switch medicines before you get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H550777193\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/0/18434?source=see_link\">",
"       Patient information: EEG (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/40/43650?source=see_link\">",
"       Patient information: Epilepsy in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/54/38754?source=see_link\">",
"       Patient information: Epilepsy in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/5/30802?source=see_link\">",
"       Patient information: Epilepsy and pregnancy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=see_link\">",
"       Patient information: Seizures in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/26/419?source=see_link\">",
"       Patient information: Seizures in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39473?source=see_link\">",
"       Patient information: Febrile seizures (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/5/19540?source=see_link\">",
"       Patient information: Treatment of seizures in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/56/28546?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15501 Version 9.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-18D72DAC39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_56_28546=[""].join("\n");
var outline_f27_56_28546=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H550777130\">",
"      What are seizures?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H550777137\">",
"      What are the symptoms of a seizure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H550777144\">",
"      Should I see a doctor or nurse if I have a seizure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H550777151\">",
"      How are seizures treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H550777158\">",
"      Do anti-seizure medicines cause side effects?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H550777165\">",
"      What if anti-seizure medicines do not work for me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H550777172\">",
"      How can I reduce my chances of having more seizures?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H550777179\">",
"      What should my family members do if they see me having a seizure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H550777186\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H550777193\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/0/18434?source=related_link\">",
"      Patient information: EEG (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/5/30802?source=related_link\">",
"      Patient information: Epilepsy and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/40/43650?source=related_link\">",
"      Patient information: Epilepsy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/54/38754?source=related_link\">",
"      Patient information: Epilepsy in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39473?source=related_link\">",
"      Patient information: Febrile seizures (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=related_link\">",
"      Patient information: Seizures in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/26/419?source=related_link\">",
"      Patient information: Seizures in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/5/19540?source=related_link\">",
"      Patient information: Treatment of seizures in children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_56_28547="Doppler waveform within stented artery";
var content_f27_56_28547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Doppler waveform within stented artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Duplex ultrasonography of a superficial femoral artery stent. Note the normal triphasic Doppler waveform within the stent, with a normal peak systolic velocity (78.6 cm per second). The bright white parallel lines represent the margins of the stent.",
"    <div class=\"footnotes\">",
"     DST: distal; M: mid; RT: right; SFA: superficial femoral artery; %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Topol EJ, Califf RM, et al. Textbook of Cardiovascular Medicine, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_56_28547=[""].join("\n");
var outline_f27_56_28547=null;
var title_f27_56_28548="Factor IX concentrates: Patient drug information";
var content_f27_56_28548=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Factor IX concentrates: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21430?source=see_link\">",
"     see \"Factor IX concentrates: Pediatric drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/61/8151?source=see_link\">",
"     see \"Factor IX concentrates: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16264034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AlphaNine&reg; SD;",
"     </li>",
"     <li>",
"      Mononine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16264035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Immunine&reg; VH",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F16328908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F16328910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hemophilia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat bleeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F16328909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702099",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to Factor IX, mice, hamsters, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F16328914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F16328915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever and chills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F16328916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F16328912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695961",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be given at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F16328913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F16328917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Most of the time, this drug will be given to you in a doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug is given at home, store unopened vials in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       May also store unopened AlphaNine&reg;SD at room temperature. Throw away any unused vials after 3 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       May also store unopened Mononine&reg; at room temperature. Throw away any unused vials after 1 month.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F16328918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88617 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-7920B88E07-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_56_28548=[""].join("\n");
var outline_f27_56_28548=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16264034\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16264035\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328908\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328910\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328909\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328914\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328915\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328916\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328912\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328913\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328917\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16328918\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/61/8151?source=related_link\">",
"      Factor IX concentrates: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21430?source=related_link\">",
"      Factor IX concentrates: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_56_28549="Respiratory muscle training and resting in COPD";
var content_f27_56_28549=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Respiratory muscle training and resting in COPD",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/56/28549/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/56/28549/contributors\">",
"     Bartolome R Celli, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/56/28549/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/56/28549/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/56/28549/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/56/28549/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/56/28549/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The respiratory muscles constitute a vital component of the respiratory pump. Their contraction during part of the breathing cycle changes the anatomic configuration of the thorax and displaces its components, so that air moves into and out of the gas exchanging portion of the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The importance of the respiratory musculature in chronic obstructive pulmonary disease (COPD) is underscored by diaphragmatic structural changes which render patients more resistant to fatigue, including an increased quantity of slow twitch fibers and slow isomers of myosin light chains, tropomyosin, and troponins [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of training and resting the respiratory muscles in patients with chronic obstructive pulmonary disease (COPD) will be presented here. An overview of the management of stable COPD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRENGTH AND ENDURANCE TRAINING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leith and Bradley first demonstrated in normal individuals that the respiratory muscles, like their skeletal muscle counterparts, could be specifically trained to improve strength or endurance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/6\">",
"     6",
"    </a>",
"    ]. Multiple studies have subsequently shown that a training response will occur if there is a sufficient stimulus.",
"   </p>",
"   <p>",
"    Since reduced inspiratory muscle strength is evident in patients with COPD, considerable efforts have been made to define the role of respiratory muscle training in this setting. Theoretically, an increase in inspiratory muscle strength (and perhaps endurance) could result in improved respiratory muscle function. However, this may only be relevant when patients must handle inspiratory loads that are greater than baseline, such as during an acute exacerbation.",
"   </p>",
"   <p>",
"    The possibility that expiratory muscle training is also beneficial was supported by a study that compared expiratory, inspiratory, and combined training [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/7\">",
"     7",
"    </a>",
"    ]. More data are needed to clarify the possible role of expiratory muscle training, which is a complex therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Strength training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Training for strength is achieved by a high intensity, short duration stimulus, such as performance of inspiratory maneuvers against a closed glottis or shutter. An increase in maximal inspiratory pressures has been demonstrated when the respiratory muscles have been specifically trained for strength [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Respiratory muscle strength has also been shown to increase as a by-product of endurance training. It is therefore possible that some of the observed benefits reported after endurance training may be related to the associated increase in strength.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Endurance training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Training for endurance is achieved by low intensity, high repetition training. Three types of programs have been used: flow resistive loading; threshold loading; and voluntary isocapnic hyperpnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Flow resistive loading",
"    </span>",
"    &nbsp;&mdash;&nbsp;In flow resistive load training, the load consists of decreasing inspiratory breath hole size. The load will increase provided that frequency, tidal volume, and inspiratory time are held constant. Although most studies in patients with COPD have shown an improvement in the time that a given respiratory load can be maintained (ventilatory muscle endurance), the results have to be interpreted with caution, since endurance can be increased with changes in the pattern of breathing.",
"   </p>",
"   <p>",
"    A number of controlled studies of resistive breathing have shown an increase in the endurance time that the ventilatory muscles could tolerate a known load [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/9-17\">",
"     9-17",
"    </a>",
"    ]. Some have also shown a significant increase in strength [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/9-11,13-16\">",
"     9-11,13-16",
"    </a>",
"    ] and exercise tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/16\">",
"     16",
"    </a>",
"    ], and a decrease in dyspnea during inspiratory loading [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/10,16\">",
"     10,16",
"    </a>",
"    ]. The pressure required to achieve training must exceed 30 percent of maximal inspiratory pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/9,16\">",
"     9,16",
"    </a>",
"    ]. In the studies which evaluated systemic exercise performance, there was a minimal increase in walking distance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/9,13,15-17\">",
"     9,13,15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, the extensive data available indicate that ventilatory muscle training with resistive breathing results in improved ventilatory muscle strength and endurance, but has marginal effects on overall exercise performance. It is not clear whether this effect results in decreased morbidity or mortality, or offers any other clinical advantage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Threshold loading",
"    </span>",
"    &nbsp;&mdash;&nbsp;With threshold loading, the patient must generate a threshold or target level of work before initiating inspiratory airflow. The threshold pressure needed to initiate inspiratory flow is high enough to ensure training, independent of inspiratory flow rate. When threshold devices are used, the breathing pattern (inspiratory time and respiratory rate) is not as critically important because the pressure required to activate the threshold is independent of the flow.",
"   </p>",
"   <p>",
"    The benefit of inspiratory threshold loading was demonstrated in a trial of 33 patients with severe COPD who were randomly assigned to receive high intensity training (highest tolerable inspiratory threshold load) or sham training (only 10 percent of the maximal inspiratory pressure) three times per week for eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/18\">",
"     18",
"    </a>",
"    ]. High intensity training resulted in a greater increase of the maximum inspiratory pressure (18 versus 5 cm H2O), maximum threshold pressure (21 versus 2 cm H2O), and six-minute walking distance (27 versus 5 meters), as well as improved dyspnea and fatigue, compared to sham training.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Voluntary isocapnic hyperpnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Voluntary isocapnic hyperpnea is a training method in which patients maintain high levels of ventilation over time (for 15 minutes, two or three times daily). Sufficient carbon dioxide is added to inspired gas to maintain a constant arterial PCO2 (measured indirectly by end-tidal PCO2).",
"   </p>",
"   <p>",
"    Studies evaluating the efficacy of respiratory muscle endurance training using voluntary isocapnic hyperpnea have had different results. Two controlled studies reported increases of maximal sustained ventilatory capacity (MSVC) in patients with COPD who were trained for six weeks, but the improvement in exercise endurance was no better than that observed in the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In contrast, a more recent study demonstrated improvement of endurance exercise capacity, respiratory muscle endurance capacity, perception of dyspnea, and quality of life compared to control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5625014\">",
"    <span class=\"h2\">",
"     Potential deleterious effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is also the potential for ventilatory muscle training to be deleterious. Breathing at a high proportion of the functional reserve or with a prolonged inspiratory time may induce muscle fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/22\">",
"     22",
"    </a>",
"    ]. Both factors are an intrinsic part of training; it is therefore possible that a sufficiently intense training program may precipitate fatigue. This may explain why compliance with such training programs is low, with up to 50 percent of patients failing to complete the studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RESPIRATORY MUSCLE RESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory muscles may fatigue when working against a sufficiently large load. This has been shown to occur experimentally in both normal volunteers and patients with COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Clinically, respiratory muscle fatigue appears to play an important role in the acute respiratory failure of patients with COPD. In comparison, patients with chronic stable COPD are not suffering from chronic respiratory muscle fatigue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Acute on chronic respiratory failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several uncontrolled trials of noninvasive positive pressure ventilation (NPPV) in acute on chronic respiratory failure suggested a benefit from respiratory muscle unloading and resting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/23\">",
"     23",
"    </a>",
"    ]. This has been confirmed in several randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. These trials evaluated different outcomes, including rate of intubation, length of stay in the intensive care unit or in the hospital, dyspnea, and mortality. Although not all studies found the same results in the most important outcomes (such as mortality), there was uniform agreement that respiratory muscle resting using NPPV was effective in reversing acute respiratory failure. As an example, one study showed that patients with COPD and acute respiratory failure who were treated with NPPV were more likely to improve without requiring intubation than those randomized to standard therapy (9 versus 67 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients best suited for this method were those with elevated arterial PCO2 who were able to cooperate with the care givers and had no other important co-morbid problems, such as sepsis or severe pneumonia. Because NPPV is potentially dangerous, patients considered for this therapy should be closely monitored and treated by individuals familiar with this ventilatory technique [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chronic stable COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility that the respiratory muscles of patients with severe COPD are functioning close to the threshold for fatigue has led numerous investigators to explore a potential role of resting the respiratory muscles with noninvasive negative or positive pressure ventilation. The data are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Numerous controlled trials have shown no benefit for most of the outcomes studied, including rate of hospitalization, quality of life, and survival [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/22,28-32\">",
"       22,28-32",
"      </a>",
"      ]. In the largest trial, exercise tolerance, arterial blood gases, frequency of decompensation, and pulmonary function were similar in treated and untreated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/29\">",
"       29",
"      </a>",
"      ]. In a randomized trial of 72 patients with hypercapnic COPD, rehabilitation was compared with rehabilitation plus nocturnal noninvasive positive pressure ventilation (NPPV) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/33\">",
"       33",
"      </a>",
"      ]. The rehabilitation plus NPPV group had greater improvements in questionnaires of health status and in PaCO2, than the group receiving rehabilitation alone. However, the improvements were of modest clinical significance.",
"     </li>",
"     <li>",
"      In contrast, several uncontrolled studies have demonstrated positive results [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/34\">",
"       34",
"      </a>",
"      ]. One study suggested that positive rather than negative pressure ventilation may be helpful in hypercapnic patients with relatively stable COPD [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28549/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory muscle training increases the strength and capacity of the muscles to endure a respiratory load. The load must be higher than 30 percent of maximal force for training to occur. Training will decrease dyspnea. Controversy remains as to whether training also improves exercise performance or performance of activities of daily living. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Strength and endurance training'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It seems logical to predict that increases in strength and endurance should help respiratory muscle function. However, this may only be relevant when patients must handle inspiratory loads that are greater than baseline, such as during an acute exacerbation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Strength and endurance training'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a limited role for intermittent respiratory muscle rest for stable patients with COPD. In contrast, available evidence supports the use of noninvasive ventilation in patients with COPD who develop acute decompensation, especially manifested with an increase in PaCO2. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Respiratory muscle resting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The exact role of respiratory muscle training, and the criteria for patient selection are less clear. However, patients with symptoms of dyspnea and evidence of respiratory muscle weakness may benefit from training. Theoretical considerations make the group of patients with COPD and acute decompensation highly unlikely to benefit from respiratory muscle training. More data are needed before recommendations can be extended to patients with different degrees of symptomatic but relatively stable COPD. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Respiratory muscle resting'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/1\">",
"      Roussos C, Macklem PT. The respiratory muscles. N Engl J Med 1982; 307:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/2\">",
"      Rochester DF. The diaphragm: contractile properties and fatigue. J Clin Invest 1985; 75:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/3\">",
"      Celli BR. Respiratory muscle function. Clin Chest Med 1986; 7:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/4\">",
"      Levine S, Kaiser L, Leferovich J, Tikunov B. Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease. N Engl J Med 1997; 337:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/5\">",
"      Testelmans D, Crul T, Maes K, et al. Atrophy and hypertrophy signalling in the diaphragm of patients with COPD. Eur Respir J 2010; 35:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/6\">",
"      Leith DE, Bradley M. Ventilatory muscle strength and endurance training. J Appl Physiol 1976; 41:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/7\">",
"      Weiner P, Magadle R, Beckerman M, et al. Comparison of specific expiratory, inspiratory, and combined muscle training programs in COPD. Chest 2003; 124:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/8\">",
"      Reid, WD, Warren, CP. Ventilatory muscle strength and endurance training in elderly subjects and patients with chronic airflow limitation: a pilot study. Physiol Canada 1984; 36:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/9\">",
"      Larson JL, Kim MJ, Sharp JT, Larson DA. Inspiratory muscle training with a pressure threshold breathing device in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1988; 138:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/10\">",
"      Harver A, Mahler DA, Daubenspeck JA. Targeted inspiratory muscle training improves respiratory muscle function and reduces dyspnea in patients with chronic obstructive pulmonary disease. Ann Intern Med 1989; 111:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/11\">",
"      Belman MJ, Shadmehr R. Targeted resistive ventilatory muscle training in chronic obstructive pulmonary disease. J Appl Physiol 1988; 65:2726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/12\">",
"      Noseda A, Carpiaux JP, Vandeput W, et al. Resistive inspiratory muscle training and exercise performance in COPD patients. A comparative study with conventional breathing retraining. Bull Eur Physiopathol Respir 1987; 23:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/13\">",
"      Weiner P, Azgad Y, Ganam R. Inspiratory muscle training combined with general exercise reconditioning in patients with COPD. Chest 1992; 102:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/14\">",
"      Belman MJ, Mittman C. Ventilatory muscle training improves exercise capacity in chronic obstructive pulmonary disease patients. Am Rev Respir Dis 1980; 121:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/15\">",
"      Wanke T, Formanek D, Lahrmann H, et al. Effects of combined inspiratory muscle and cycle ergometer training on exercise performance in patients with COPD. Eur Respir J 1994; 7:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/16\">",
"      Lisboa C, Mu&ntilde;oz V, Beroiza T, et al. Inspiratory muscle training in chronic airflow limitation: comparison of two different training loads with a threshold device. Eur Respir J 1994; 7:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/17\">",
"      Ramirez-Sarmiento A, Orozco-Levi M, Guell R, et al. Inspiratory muscle training in patients with chronic obstructive pulmonary disease: structural adaptation and physiologic outcomes. Am J Respir Crit Care Med 2002; 166:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/18\">",
"      Hill K, Jenkins SC, Philippe DL, et al. High-intensity inspiratory muscle training in COPD. Eur Respir J 2006; 27:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/19\">",
"      Ries AL, Moser KM. Comparison of isocapnic hyperventilation and walking exercise training at home in pulmonary rehabilitation. Chest 1986; 90:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/20\">",
"      Levine S, Weiser P, Gillen J. Evaluation of a ventilatory muscle endurance training program in the rehabilitation of patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/21\">",
"      Koppers RJ, Vos PJ, Boot CR, Folgering HT. Exercise performance improves in patients with COPD due to respiratory muscle endurance training. Chest 2006; 129:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/22\">",
"      Celli B, Lee H, Criner G, et al. Controlled trial of external negative pressure ventilation in patients with severe chronic airflow obstruction. Am Rev Respir Dis 1989; 140:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/23\">",
"      Brochard L, Isabey D, Piquet J, et al. Reversal of acute exacerbations of chronic obstructive lung disease by inspiratory assistance with a face mask. N Engl J Med 1990; 323:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/24\">",
"      Kramer N, Meyer TJ, Meharg J, et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 1995; 151:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/25\">",
"      Bott J, Carroll MP, Conway JH, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet 1993; 341:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/26\">",
"      Brochard, L, Wysocki, M, Lofaso, F, et al. Face mask inspiratory positive airway pressure (IPAP) for acute exacerbation of chronic respiratory insufficiency . A randomized study. Am Rev Respir Dis 1993; 147:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/27\">",
"      Hill NS. Noninvasive ventilation for chronic obstructive pulmonary disease. Respir Care 2004; 49:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/28\">",
"      Zibrak JD, Hill NS, Federman EC, et al. Evaluation of intermittent long-term negative-pressure ventilation in patients with severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1988; 138:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/29\">",
"      Shapiro SH, Ernst P, Gray-Donald K, et al. Effect of negative pressure ventilation in severe chronic obstructive pulmonary disease. Lancet 1992; 340:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/30\">",
"      Strumpf DA, Millman RP, Carlisle CC, et al. Nocturnal positive-pressure ventilation via nasal mask in patients with severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 144:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/31\">",
"      Casanova C, Celli BR, Tost L, et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. Chest 2000; 118:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/32\">",
"      Clini E, Sturani C, Rossi A, et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J 2002; 20:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/33\">",
"      Duiverman ML, Wempe JB, Bladder G, et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax 2008; 63:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/34\">",
"      Zema MJ, Masters AP, Margouleff D. Dyspnea: the heart or the lungs? Differentiation at bedside by use of the simple Valsalva maneuver. Chest 1984; 85:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28549/abstract/35\">",
"      Meecham Jones DJ, Paul EA, Jones PW, Wedzicha JA. Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. Am J Respir Crit Care Med 1995; 152:538.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1452 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-1D72A0B336-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_56_28549=[""].join("\n");
var outline_f27_56_28549=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRENGTH AND ENDURANCE TRAINING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Strength training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Endurance training",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Flow resistive loading",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Threshold loading",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Voluntary isocapnic hyperpnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5625014\">",
"      Potential deleterious effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RESPIRATORY MUSCLE RESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Acute on chronic respiratory failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chronic stable COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_56_28550="Lipid abnormalities in thyroid disease";
var content_f27_56_28550=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lipid abnormalities in thyroid disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/56/28550/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/56/28550/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/56/28550/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/56/28550/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/56/28550/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/56/28550/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/56/28550/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A relationship between hypothyroidism, lipid disorders, and coronary artery disease was first suggested in the 1960s [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/1\">",
"     1",
"    </a>",
"    ]. This was at a time when the diagnosis of hypothyroidism was based upon symptoms and signs, and sometimes serum cholesterol measurements, rather than measurements of serum thyroxine (T4) and thyrotropin (TSH). In some cases, a high serum cholesterol concentration was regarded as evidence for \"premyxoedema\" in the absence of symptoms of hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/2\">",
"     2",
"    </a>",
"    ]. How many of these patients in fact had hypothyroidism is not known. While there is no doubt that many hypothyroid patients have abnormal serum lipid concentrations, the increased risk of coronary artery disease seen in hypothyroid patients is likely multifactorial in etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3046?source=see_link\">",
"     \"Cardiovascular effects of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERT HYPOTHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many hypothyroid patients have high serum concentrations of total cholesterol and low-density-lipoprotein (LDL) cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/3\">",
"     3",
"    </a>",
"    ], and some have high serum concentrations of triglycerides [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/4\">",
"     4",
"    </a>",
"    ], intermediate-density lipoproteins [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/5\">",
"     5",
"    </a>",
"    ], apoprotein A-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/6\">",
"     6",
"    </a>",
"    ] and apoprotein B [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=see_link\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of 295 hypothyroid patients, the following patterns of serum lipids were noted, using the Frederickson classification [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type IIa (hypercholesterolemia) &mdash; 56 percent",
"     </li>",
"     <li>",
"      Type IIb (hypercholesterolemia and hypertriglyceridemia) &mdash; 34 percent",
"     </li>",
"     <li>",
"      Type IV (hypertriglyceridemia) &mdash; 1.5 percent",
"     </li>",
"     <li>",
"      No abnormality &mdash; 8.5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With respect to serum high-density-lipoprotein (HDL) cholesterol concentrations, high, normal or low values have been reported in different series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Among the subfractions of HDL cholesterol, it is the HDL2, not HDL3, fraction that may be high in hypothyroidism and normalize during thyroxine (T4) therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/8,12\">",
"     8,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The excess risk of coronary heart disease observed with hypothyroidism has been thought to be due, at least in part, to the characteristic lipid abnormalities (including high LDL). However, in a study using NMR spectroscopy to assess lipid subparticle concentrations, hypothyroid women had a shift toward less atherogenic large LDL, small VLDL, and large HDL subparticle sizes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Effect of T4 therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in serum lipoprotein(a) concentrations in hypothyroidism and during T4 therapy have also varied. In some patients, serum lipoprotein(a) concentrations are high and fall during T4 therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/7,14,15\">",
"     7,14,15",
"    </a>",
"    ], whereas others have normal values that do not change during therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/6,8,16,17\">",
"     6,8,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An analysis of 19 published studies evaluated the effects of T4 therapy on the serum total cholesterol concentration in patients with overt hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients with an initial value of 310",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or less had a mean fall of 46",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    during T4 therapy; those with an initial value of more than 310",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    had a much greater mean fall of 131",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    Remnant lipoprotein concentrations (intermediate density lipoproteins), a predictor of coronary heart disease risk, may also be elevated in overt hypothyroidism with a lowering in response to T4 therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/19\">",
"     19",
"    </a>",
"    ]. The same investigators have reported similar findings in patients with subclinical hypothyroidism. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Subclinical hypothyroidism'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Non-high-density lipoprotein cholesterol (total cholesterol minus HDL cholesterol) was also lowered in both overt and subclinical hypothyroidism after T4 therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary mechanism for hypercholesterolemia in hypothyroidism is accumulation of LDL cholesterol due to a reduction in the number of cell surface receptors for LDL [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/21\">",
"     21",
"    </a>",
"    ], resulting in decreased catabolism of LDL. A decrease in LDL receptor activity has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extent of upregulation of the LDL receptor by T4 therapy varies considerably in patients with different polymorphisms of the LDL receptor gene. In one study, patients homozygous for one specific genotype",
"    <span class=\"nowrap\">",
"     (-/-)",
"    </span>",
"    had a four-fold greater reduction in serum cholesterol during T4 therapy than those who were homozygous for a different genotype",
"    <span class=\"nowrap\">",
"     (+/+)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other mechanisms also may affect the serum cholesterol concentration in hypothyroidism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LDL oxidation is significantly increased in hypothyroid patients, the degree of which is directly related to the serum LDL cholesterol concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diminished secretion of cholesterol into bile has been demonstrated in hypothyroid rats [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced cholesteryl ester transfer (the net transfer of cholesterol from HDL to LDL and very-low-density-lipoprotein [VLDL]) in hypothyroidism may minimize the increase in serum LDL cholesterol concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A different mechanism, reduced lipoprotein lipase activity, is responsible for the development of hypertriglyceridemia in hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/3,27\">",
"     3,27",
"    </a>",
"    ]. The rate of synthesis of triglycerides was normal in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/27\">",
"     27",
"    </a>",
"    ], but increased in another [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chylomicron remnants accumulate in hypothyroidism and are cleared more rapidly during T4 treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prevalence of hypothyroidism in patients with hyperlipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate question is the frequency of hypothyroidism among patients with hypercholesterolemia. In a study of 1210 patients with serum total cholesterol concentrations above 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.2",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    the prevalence of overt hypothyroidism was 1.3 percent and that of subclinical hypothyroidism was 11.2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/30\">",
"     30",
"    </a>",
"    ]. In another study of 248 patients referred to a lipid disorders clinic, 2.8 percent had overt hypothyroidism and 4.4 percent had subclinical hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, all patients with hypercholesterolemia (and hypertriglyceridemia) should be screened for hypothyroidism (and other secondary causes of hyperlipidemia) before being given specific lipid-lowering drug therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnosis of and screening for hypothyroidism\", section on 'Candidates for screening'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43621?source=see_link\">",
"     \"Secondary causes of dyslipidemia\"",
"    </a>",
"    .) If hypothyroidism is present, the patient should be treated for three to four months with T4. If the serum lipid concentrations are not then normal, specific lipid-lowering therapy may be indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients in the latter group presumably have hypothyroidism superimposed upon primary hyperlipidemia. The effect of hypothyroidism varies with the underlying lipid disorder: it can raise serum intermediate-density-lipoprotein cholesterol concentrations in patients with \"broad beta\" disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/5\">",
"     5",
"    </a>",
"    ], exacerbate hypercholesterolemia in patients with familial hypercholesterolemia (who have an underlying defect in the LDL receptor) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/32\">",
"     32",
"    </a>",
"    ], and exacerbate hypertriglyceridemia in patients with familial hypertriglyceridemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hypothyroidism, autoimmunity, and coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary heart disease is increased among patients with overt hypothyroidism; however, in addition to abnormal lipid concentrations, diastolic hypertension (often present in hypothyroidism), as well as abnormalities in endothelial function, C-reactive protein, and other parameters, may be contributing factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3046?source=see_link\">",
"     \"Cardiovascular effects of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study, thyroid antibodies were a risk factor for coronary disease independent of serum cholesterol concentrations or the systemic blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/34\">",
"     34",
"    </a>",
"    ]. In another study, euthyroid, normocholesterolemic men and postmenopausal women with either antithyroglobulin or antithyroid peroxidase antibodies had high serum lipoprotein(a) concentrations, which may be a risk factor for coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=see_link\">",
"     \"Lipoprotein(a) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUBCLINICAL HYPOTHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with subclinical hypothyroidism have normal serum lipid concentrations. However, some have slightly high serum total and LDL cholesterol and lipoprotein(a) concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/6,18,36-38\">",
"     6,18,36-38",
"    </a>",
"    ]. The effects of T4 treatment on patients with subclinical hypothyroidism were similar in two randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/38,39\">",
"     38,39",
"    </a>",
"    ] and two reviews of the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/18,37\">",
"     18,37",
"    </a>",
"    ]: a mean reduction in serum total cholesterol of 9 to 15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.2 to 0.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and in LDL cholesterol of 11",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/18,37\">",
"     18,37",
"    </a>",
"    ]. The effect of T4 may be more pronounced in those with overt hypercholesterolemia; in one study, as an example, serum LDL-cholesterol fell by 36",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.9",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    p&lt;0.01) in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of T4 treatment on serum lipoprotein (a) concentrations in these patients are variable; in two studies, they declined by as much as 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], but did not change in another study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum HDL cholesterol concentrations are low [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/36,43,44\">",
"     36,43,44",
"    </a>",
"    ] or normal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/45-47\">",
"     45-47",
"    </a>",
"    ] in patients with subclinical hypothyroidism. The response to T4 therapy has been variable, but in the meta-analysis the serum HDL cholesterol concentration did not increase significantly [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Remnant lipoprotein concentrations (intermediate density lipoproteins), a predictor of coronary heart disease risk, may also be elevated in both overt and subclinical hypothyroidism with a lowering in response to T4 therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coronary heart disease may be increased among patients with subclinical hypothyroidism. However, the data are conflicting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=see_link&amp;anchor=H10#H10\">",
"     \"Subclinical hypothyroidism\", section on 'Cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HYPERTHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hyperthyroidism have changes in lipid metabolism generally opposite to those described above for hypothyroidism. Serum total, LDL and HDL cholesterol concentrations tend to be low [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/49\">",
"     49",
"    </a>",
"    ], as do serum apoprotein-B concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/7\">",
"     7",
"    </a>",
"    ]. Fatty acid clearance is increased, but lipolysis is increased even more, resulting in high serum fatty acid concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/4\">",
"     4",
"    </a>",
"    ]. Serum lipoprotein(a) concentrations were low in one study, but did not increase during antithyroid drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28550/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6582291\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypothyroid patients have increased serum total and LDL cholesterol levels. Many also have high serum triglycerides, intermediate-density lipoproteins, apo A-1 and apo B concentrations. T4 therapy may reduce total and LDL cholesterol and intermediate density lipoprotein concentrations, especially in patients with significant elevations prior to treatment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overt hypothyroidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Similar findings are noted in patients with subclinical hypothyroidism whose TSH concentrations are &gt;10",
"      <span class=\"nowrap\">",
"       mIU/L.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=see_link&amp;anchor=H10#H10\">",
"       \"Subclinical hypothyroidism\", section on 'Cardiovascular disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients with hyperlipidemia, overt and subclinical hypothyroidism are common. Thus, patients with hypercholesterolemia (and hypertriglyceridemia) should be screened for hypothyroidism (and other secondary causes of hyperlipidemia) before being given specific lipid-lowering drug therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Prevalence of hypothyroidism in patients with hyperlipidemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The increased risk of coronary artery disease seen in hypothyroid patients is likely multifactorial due to elevated lipids, diastolic hypertension, elevated C-reactive protein, endothelial dysfunction, and other factors. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hypothyroidism, autoimmunity, and coronary heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperthyroidism is associated with lower levels of total, LDL, and HDL cholesterol. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hyperthyroidism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/1\">",
"      Bastenie PA, Vanhaelst L, Neve P. Coronary-artery disease in hypothyroidism. Lancet 1967; 2:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/2\">",
"      Fowler PS, Swale J. Premyxoedema and coronary-artery disease. Lancet 1967; 1:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/3\">",
"      Lithell H, Boberg J, Hellsing K, et al. Serum lipoprotein and apolipoprotein concentrations and tissue lipoprotein-lipase activity in overt and subclinical hypothyroidism: the effect of substitution therapy. Eur J Clin Invest 1981; 11:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/4\">",
"      Nikkila, E, Kekki, M. Plasma triglyceride metabolism in thyroid disease. J Clin Invest 1973; 51:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/5\">",
"      Hazzard WR, Bierman EL. Aggravation of broad- disease (type 3 hyperlipoproteinemia) by hypothyroidism. Arch Intern Med 1972; 130:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/6\">",
"      Arem R, Escalante DA, Arem N, et al. Effect of L-thyroxine therapy on lipoprotein fractions in overt and subclinical hypothyroidism, with special reference to lipoprotein(a). Metabolism 1995; 44:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/7\">",
"      de Bruin TW, van Barlingen H, van Linde-Sibenius Trip M, et al. Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid, and hyperthyroid subjects. J Clin Endocrinol Metab 1993; 76:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/8\">",
"      Pazos F, Alvarez JJ, Rubi&eacute;s-Prat J, et al. Long-term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins. J Clin Endocrinol Metab 1995; 80:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/9\">",
"      O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993; 68:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/10\">",
"      Muls E, Rosseneu M, Blaton V, et al. Serum lipids and apolipoproteins A-I, A-II and B in primary hypothyroidism before and during treatment. Eur J Clin Invest 1984; 14:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/11\">",
"      Agdeppa D, Macaron C, Mallik T, Schnuda ND. Plasma high density lipoprotein cholesterol in thyroid disease. J Clin Endocrinol Metab 1979; 49:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/12\">",
"      Verdugo C, Perrot L, Ponsin G, et al. Time-course of alterations of high density lipoproteins (HDL) during thyroxine administration to hypothyroid women. Eur J Clin Invest 1987; 17:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/13\">",
"      Pearce EN, Wilson PW, Yang Q, et al. Thyroid function and lipid subparticle sizes in patients with short-term hypothyroidism and a population-based cohort. J Clin Endocrinol Metab 2008; 93:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/14\">",
"      Mart&iacute;nez-Triguero ML, Hern&aacute;ndez-Mijares A, Nguyen TT, et al. Effect of thyroid hormone replacement on lipoprotein(a), lipids, and apolipoproteins in subjects with hypothyroidism. Mayo Clin Proc 1998; 73:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/15\">",
"      Tzotzas T, Krassas GE, Konstantinidis T, Bougoulia M. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 2000; 10:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/16\">",
"      Spandrio S, Sleiman I, Scalvini T, et al. Lipoprotein (a) in thyroid dysfunction before and after treatment. Horm Metab Res 1993; 25:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/17\">",
"      Klausen IC, Nielsen FE, Heged&uuml;s L, et al. Treatment of hypothyroidism reduces low-density lipoproteins but not lipoprotein(a). Metabolism 1992; 41:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/18\">",
"      Tanis BC, Westendorp GJ, Smelt HM. Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies. Clin Endocrinol (Oxf) 1996; 44:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/19\">",
"      Ito M, Takamatsu J, Matsuo T, et al. Serum concentrations of remnant-like particles in hypothyroid patients before and after thyroxine replacement. Clin Endocrinol (Oxf) 2003; 58:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/20\">",
"      Ito M, Arishima T, Kudo T, et al. Effect of levo-thyroxine replacement on non-high-density lipoprotein cholesterol in hypothyroid patients. J Clin Endocrinol Metab 2007; 92:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/21\">",
"      Thompson GR, Soutar AK, Spengel FA, et al. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo. Proc Natl Acad Sci U S A 1981; 78:2591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/22\">",
"      Hoogerbrugge N, Jansen H, Staels B, et al. Growth hormone normalizes low-density lipoprotein receptor gene expression in hypothyroid rats. Metabolism 1996; 45:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/23\">",
"      Wiseman SA, Powell JT, Humphries SE, Press M. The magnitude of the hypercholesterolemia of hypothyroidism is associated with variation in the low density lipoprotein receptor gene. J Clin Endocrinol Metab 1993; 77:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/24\">",
"      Costantini F, Pierdomenico SD, De Cesare D, et al. Effect of thyroid function on LDL oxidation. Arterioscler Thromb Vasc Biol 1998; 18:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/25\">",
"      FRIEDMAN M, BYERS SO, ROSENMAN RH. Changes in excretion of intestinal cholesterol and sterol digitonides in hyper and hypothyroidism. Circulation 1952; 5:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/26\">",
"      Ritter MC, Kannan CR, Bagdade JD. The effects of hypothyroidism and replacement therapy on cholesteryl ester transfer. J Clin Endocrinol Metab 1996; 81:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/27\">",
"      Pyk&auml;list&ouml; O, Goldberg AP, Brunzell JD. Reversal of decreased human adipose tissue lipoprotein lipase and hypertriglyceridemia after treatment of hypothyroidism. J Clin Endocrinol Metab 1976; 43:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/28\">",
"      Gjedde S, Gormsen LC, Rungby J, et al. Decreased lipid intermediate levels and lipid oxidation rates despite normal lipolysis in patients with hypothyroidism. Thyroid 2010; 20:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/29\">",
"      Weintraub M, Grosskopf I, Trostanesky Y, et al. Thyroxine replacement therapy enhances clearance of chylomicron remnants in patients with hypothyroidism. J Clin Endocrinol Metab 1999; 84:2532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/30\">",
"      Bruckert E, De Gennes JL, Dairou F, Turpin G. [Frequency of hypothyroidism in a population of hyperlipidemic subjects]. Presse Med 1993; 22:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/31\">",
"      Tsimihodimos V, Bairaktari E, Tzallas C, et al. The incidence of thyroid function abnormalities in patients attending an outpatient lipid clinic. Thyroid 1999; 9:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/32\">",
"      Illingworth DR, McClung MR, Connor WE, Alaupovic P. Familial hypercholesterolaemia and primary hypothyroidism: coexistence of both disorders in a young woman with severe hypercholesterolaemia. Clin Endocrinol (Oxf) 1981; 14:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/33\">",
"      Chait A, Brunzell JD. Severe hypertriglyceridemia: role of familial and acquired disorders. Metabolism 1983; 32:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/34\">",
"      Ti&egrave;che M, Lupi GA, Gutzwiller F, et al. Borderline low thyroid function and thyroid autoimmunity. Risk factors for coronary heart disease? Br Heart J 1981; 46:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/35\">",
"      Lotz H, Salab&egrave; GB. Lipoprotein(a) increase associated with thyroid autoimmunity. Eur J Endocrinol 1997; 136:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/36\">",
"      Kung AW, Pang RW, Janus ED. Elevated serum lipoprotein(a) in subclinical hypothyroidism. Clin Endocrinol (Oxf) 1995; 43:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/37\">",
"      Danese MD, Ladenson PW, Meinert CL, Powe NR. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 2000; 85:2993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/38\">",
"      Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab 2002; 87:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/39\">",
"      Meier C, Staub JJ, Roth CB, et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001; 86:4860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/40\">",
"      Michalopoulou G, Alevizaki M, Piperingos G, et al. High serum cholesterol levels in persons with 'high-normal' TSH levels: should one extend the definition of subclinical hypothyroidism? Eur J Endocrinol 1998; 138:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/41\">",
"      Yildirimkaya M, Ozata M, Yilmaz K, et al. Lipoprotein(a) concentration in subclinical hypothyroidism before and after levo-thyroxine therapy. Endocr J 1996; 43:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/42\">",
"      Ganotakis ES, Mandalaki K, Tampakaki M, et al. Subclinical hypothyroidism and lipid abnormalities in older women attending a vascular disease prevention clinic: effect of thyroid replacement therapy. Angiology 2003; 54:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/43\">",
"      Althaus BU, Staub JJ, Ryff-De L&egrave;che A, et al. LDL/HDL-changes in subclinical hypothyroidism: possible risk factors for coronary heart disease. Clin Endocrinol (Oxf) 1988; 28:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/44\">",
"      Caron P, Calazel C, Parra HJ, et al. Decreased HDL cholesterol in subclinical hypothyroidism: the effect of L-thyroxine therapy. Clin Endocrinol (Oxf) 1990; 33:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/45\">",
"      Parle JV, Franklyn JA, Cross KW, et al. Circulating lipids and minor abnormalities of thyroid function. Clin Endocrinol (Oxf) 1992; 37:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/46\">",
"      Bogner U, Arntz HR, Peters H, Schleusener H. Subclinical hypothyroidism and hyperlipoproteinaemia: indiscriminate L-thyroxine treatment not justified. Acta Endocrinol (Copenh) 1993; 128:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/47\">",
"      Staub JJ, Althaus BU, Engler H, et al. Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. Am J Med 1992; 92:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/48\">",
"      Ito M, Takamatsu J, Sasaki I, et al. Disturbed metabolism of remnant lipoproteins in patients with subclinical hypothyroidism. Am J Med 2004; 117:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28550/abstract/49\">",
"      Hoppichler F, Sandholzer C, Moncayo R, et al. Thyroid hormone (fT4) reduces lipoprotein(a) plasma levels. Atherosclerosis 1995; 115:65.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7857 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_56_28550=[""].join("\n");
var outline_f27_56_28550=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6582291\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERT HYPOTHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Effect of T4 therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prevalence of hypothyroidism in patients with hyperlipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hypothyroidism, autoimmunity, and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUBCLINICAL HYPOTHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HYPERTHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6582291\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3046?source=related_link\">",
"      Cardiovascular effects of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=related_link\">",
"      Lipoprotein(a) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43621?source=related_link\">",
"      Secondary causes of dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=related_link\">",
"      Subclinical hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_56_28551="Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)";
var content_f27_56_28551=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/56/28551/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/56/28551/contributors\">",
"     Peter A Nigrovic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/56/28551/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/56/28551/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/56/28551/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/56/28551/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/56/28551/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/56/28551/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many well-known disorders of immune excess result from a failure of",
"    <span class=\"nowrap\">",
"     self/non-self",
"    </span>",
"    discrimination by T and B lymphocytes, the effector cells of the adaptive arm of the immune system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3992?source=see_link\">",
"     \"Overview of autoimmunity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A second category of immune-mediated disease results from inappropriate activation of antigen-independent inflammatory mechanisms. This group of disorders has been termed the autoinflammatory diseases. An overview of the autoinflammatory diseases is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=see_link\">",
"     \"Periodic fever syndromes and other autoinflammatory diseases: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Autoinflammatory diseases prominently involve cells of the innate immune system as well as the mediators associated with these cells. Thus, autoinflammatory diseases are broadly considered to represent primary diseases of innate immunity, in contrast to the",
"    <strong>",
"     autoimmune",
"    </strong>",
"    diseases that result from aberrant adaptive or acquired immunity. However, this separation is far from absolute.",
"   </p>",
"   <p>",
"    The best-characterized autoinflammatory diseases are relatively rare, but florid, conditions that arise from mutations in single genes. The prototypical autoinflammatory disorders are the periodic fever syndromes. One of these disorders, the tumor necrosis factor (TNF) receptor-1 associated periodic syndrome (TRAPS; MIM #142680, formerly known as familial Hibernian fever) is the subject of this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;TRAPS is a rare disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/1\">",
"     1",
"    </a>",
"    ]. While originally described in an Irish (Hibernian) kindred, cases have since been reported in many ethnic groups. Thus, ancestry should not exclude consideration of the disorder in the appropriate setting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;TRAPS is inherited in an autosomal dominant fashion with incomplete penetrance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The genetic defect in TRAPS resides in the gene that encodes the 55 kDa receptor for tumor necrosis factor, TNFR1 (TNFRSF1A gene; MIM *191190) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In many but not all cases, mutations result in impaired shedding of this receptor.",
"   </p>",
"   <p>",
"    There is no exact correlation between genetic mutation and clinical phenotype. However, the risk of secondary (AA) amyloidosis is increased among patients with mutations affecting certain cysteine residues. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Secondary (AA) amyloidosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The pathogenesis of human TRAPS remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/7\">",
"     7",
"    </a>",
"    ]. Impaired shedding of TNFR1 eliminates an endogenous antagonist to circulating TNF. However, since some patients have normal levels of soluble TNF receptor, other mechanisms are likely. An excess of retained surface TNFR1 may result in enhanced susceptibility to TNF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/8\">",
"     8",
"    </a>",
"    ]. Conversely, mutant receptor may bind TNF less efficiently leading to impaired TNF-driven apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Finally, mutant TNFR1 may misfold",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    traffic aberrantly within the cell, triggering an unfolded protein response or initiating TNF-independent signaling within the cell that is potentially mediated by enhanced production of mitochondrial-derived reactive oxygen species that disturb intracellular signaling pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/11-14\">",
"     11-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may present from infancy to the 40s and even beyond; the median age of onset is three years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/1,15,16\">",
"     1,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent fevers over months or years, in the absence of associated viral or bacterial infections, are characteristic of TRAPS. Febrile episodes every five to six weeks are typical, though clockwork periodicity is lacking. Precipitating factors are generally not identified, though some patients or caregivers observe that physical and emotional stress may tend to trigger attacks. Fever and associated symptoms commonly last at least five days and often continue for more than two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/1,17\">",
"     1,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other clinical features include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/1,17\">",
"     1,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Focal myalgias, sometimes migratory",
"     </li>",
"     <li>",
"      Conjunctivitis",
"     </li>",
"     <li>",
"      Periorbital edema",
"     </li>",
"     <li>",
"      Abdominal pain",
"     </li>",
"     <li>",
"      Monoarticular arthritis",
"     </li>",
"     <li>",
"      Rash",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rash may take a relatively characteristic form, with single or multiple erythematous patches that may spread distally down an extremity over time [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/18\">",
"     18",
"    </a>",
"    ]. Presentation as recurrent pericarditis has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Secondary (AA) amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of patients develop clinical manifestations of secondary (AA) amyloidosis (approximately 15 percent in the United States), which primarily involves the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/1,20-22\">",
"     1,20-22",
"    </a>",
"    ]. However, the liver, thyroid, and other organs may be affected. The signs and symptoms of amyloidosis with TRAPS are similar to those observed with secondary amyloidosis in other disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link&amp;anchor=H10#H10\">",
"     \"An overview of amyloidosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of secondary (AA) amyloidosis is increased among patients with mutations affecting certain cysteine residues [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/20\">",
"     20",
"    </a>",
"    ]. The cysteines are involved in the formation of intramolecular disulfide bonds that help to maintain the three-dimensional structure of TNFR1. Since 24 percent of patients with cysteine mutations develop amyloidosis, compared with only 2 percent of patients with other mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/1,20\">",
"     1,20",
"    </a>",
"    ], the identification of an individual patient's mutation may drive therapeutic decisions. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory investigation reveals elevation of inflammatory markers including the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Such markers are particularly elevated during attacks but commonly remain modestly elevated even during asymptomatic periods. Autoantibodies such as rheumatoid factor and antinuclear antibodies (ANA) are usually absent or are present at low titer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with involvement of the kidney and other organs with AA amyloid may have proteinuria, renal insufficiency, and evidence of dysfunction of involved organs. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link&amp;anchor=H10#H10\">",
"     \"An overview of amyloidosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy of skin reveals superficial and deep infiltration by lymphocytes and monocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/15\">",
"     15",
"    </a>",
"    ]. A monocytic fasciitis, rather than a true myositis, appears to be responsible for myalgia; serum levels of muscle enzymes are normal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among those with AA amyloidosis, the deposits appear as amorphous hyaline material on light microscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link&amp;anchor=H21#H21\">",
"     \"An overview of amyloidosis\", section on 'Biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of TRAPS should be entertained only after bacterial and other infectious and neoplastic causes of recurrent fever have been excluded. In such patients, the diagnosis of TRAPS is suggested by a history of recurrent fever and one or more of the other clinical features noted above.",
"   </p>",
"   <p>",
"    Particular hallmarks of TRAPS include the protracted duration of attacks, rash, eye and periorbital involvement in more than 80 percent of patients, and the nearly uniform presence of focal myalgias [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/1\">",
"     1",
"    </a>",
"    ]. Family history is commonly positive, although some carriers of TRAPS mutations may be entirely asymptomatic.",
"   </p>",
"   <p>",
"    The diagnosis of TRAPS is confirmed by genetic testing for common mutations in the TNFR1 gene. Testing is available commercially.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of recurrent fever is broad, including connective tissue diseases, other autoinflammatory diseases, and a number of other disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Recurrent fevers due to bacterial and other infectious and neoplastic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, a diagnosis of TRAPS should be entertained only after bacterial and other infectious and neoplastic causes of recurrent fever have been excluded. (See appropriate topic reviews.)",
"   </p>",
"   <p>",
"    In addition, patients with TRAPS and other periodic fevers are often evaluated initially for fever of unknown origin (FUO). General approaches to the child and to the adult with FUO are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9706?source=see_link\">",
"     \"Approach to the child with fever of unknown origin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31927?source=see_link\">",
"     \"Approach to the adult with fever of unknown origin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Connective tissue diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic lupus erythematosus (SLE) and Still's disease in children and adults can also present with fever, pain, and skin rash. Unlike TRAPS, patients with SLE almost invariably have antinuclear antibodies and often have hypocomplementemia, glomerulonephritis, and cytopenias, which are not seen with TRAPS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=see_link\">",
"     \"Systemic lupus erythematosus in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no definitive diagnostic test for Still's disease. However, Still's disease would not typically present with recurrent, self-limited febrile episodes, as are typical of TRAPS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/3/11320?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult Still's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=see_link\">",
"     \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other autoinflammatory diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain clinical features help to distinguish TRAPS from other autoinflammatory disorders. The duration of fever is a particularly useful discriminant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=see_link\">",
"     \"Periodic fever syndromes and other autoinflammatory diseases: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Familial Mediterranean fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial Mediterranean fever (FMF) is an autosomal recessive disorder characterized by episodic attacks of fever lasting one to three days and accompanied, in most cases, by abdominal pain, pleurisy, and",
"    <span class=\"nowrap\">",
"     arthralgias/arthritis",
"    </span>",
"    from accompanying serositis and synovitis. Unlike TRAPS, rash is unusual in FMF. The diagnosis of FMF may be strongly suggested by patient ethnicity: Sephardic Jews, Armenians, North Africans, and Turks, and, to a lesser extent, Ashkenazi Jews, Greeks, and Italians. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial Mediterranean fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Hyper-IgD syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperimmunoglobulin D syndrome (Hyper-IgD syndrome or HIDS) is an autosomal recessive periodic fever syndrome most prevalent among patients of Dutch and French origin. Episodic attacks of fever lasting three to seven days are accompanied, in most cases, by chills, cervical lymphadenopathy, abdominal pain, vomiting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea. Other symptoms include headache,",
"    <span class=\"nowrap\">",
"     arthralgias/arthritis,",
"    </span>",
"    aphthous ulceration, a pleomorphic rash, and, occasionally, splenomegaly. Elevated levels of IgD (&gt;100 international",
"    <span class=\"nowrap\">",
"     units/mL)",
"    </span>",
"    are often present, a finding that is not typically seen in TRAPS. Genetic testing is used to confirm the diagnosis of HIDS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3768?source=see_link\">",
"     \"Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     PFAPA syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <strong>",
"     P",
"    </strong>",
"    eriodic",
"    <strong>",
"     F",
"    </strong>",
"    evers with",
"    <strong>",
"     A",
"    </strong>",
"    phthous stomatitis,",
"    <strong>",
"     P",
"    </strong>",
"    haryngitis, and",
"    <strong>",
"     A",
"    </strong>",
"    denitis (PFAPA) is a syndrome for which the underlying etiology and pathogenesis are uncertain. Febrile episodes of abrupt onset last three to six days and are typically accompanied by one or more of the following: pharyngitis (exudative or nonexudative), mild aphthous ulcerations, and lymphadenopathy. Other than fever, these clinical features are not typically observed in TRAPS. Recurrences of fever generally occur with nearly clockwork regularity, and laboratory markers of inflammation return to normal between episodes. There is as yet no confirmatory laboratory test for PFAPA, though the ability to &ldquo;abort&rdquo; an attack with a dose or two of steroids is highly suggestive for the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8377?source=see_link\">",
"     \"Periodic fever with aphthous stomatitis, pharyngitis and adenitis (PFAPA syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Cyclic neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclic neutropenia may occur in both children and adults. It is characterized by periods of severe neutropenia that typically last one week during each monthly cycle. When neutropenic, patients are prone to malaise, fever, aphthous stomatitis, and, occasionally, serious infections. Cyclic neutropenia is suggested by documented neutropenia with an absolute neutrophil count below",
"    <span class=\"nowrap\">",
"     500/microL",
"    </span>",
"    on at least three to five consecutive days per cycle of each of three regularly spaced cycles, a finding not observed in TRAPS. Frequent monitoring of blood counts is necessary to observe the nadir. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=see_link\">",
"     \"Cyclic neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether or not asymptomatic relatives of an affected individual should undergo genetic testing is uncertain. However, amyloidosis may develop in the absence of febrile episodes, and some authors have suggested that genetic analysis and counseling be provided to asymptomatic family members [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/21\">",
"     21",
"    </a>",
"    ]. If a mutation is detected, these individuals should be followed carefully and should be treated if evidence of amyloidosis-related organ dysfunction is noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment of TRAPS are to control symptoms, to prevent recurrent attacks, and to reduce the risk of amyloidosis, particularly in patients bearing cysteine mutations. Data from ongoing clinical trials are awaited to help determine whether all patients or only those with mutations that confer a high risk for amyloidosis should receive continuous suppressive treatment.",
"   </p>",
"   <p>",
"    Unlike FMF, TRAPS responds poorly to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , and newer biologic anti-inflammatory agents are typically used for disease control. Patients with persistent symptoms or those who develop amyloidosis despite biologic therapy should be referred to regional or national centers specializing in the investigation and care of this rare disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) may help to control fever, but glucocorticoids are typically required to terminate other clinical features of an attack. For patients with an established diagnosis of TRAPS and a typical attack, we suggest use of an oral glucocorticoid. A typical agent is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (initial dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    followed by a gradual taper and discontinuation after 7 to 10 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Anti-TNF therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with TRAPS exhibit deficient shedding of the TNFR1 receptor, which serves as an endogenous antagonist to circulating TNF. A synthetic analog of this &ldquo;natural&rdquo; TNF blocker is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , a fusion protein consisting of two copies of the 75kDa TNF receptor (TNFR2) bound to the Fc portion of human IgG. Etanercept can be highly effective in many patients with TRAPS, though not all respond and though the response is sometimes partial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/1,25,26\">",
"     1,25,26",
"    </a>",
"    ]. Etanercept is initiated at typical doses of 50 mg administered subcutaneously once weekly in adults and 0.8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (up to 50 mg) weekly in children.",
"   </p>",
"   <p>",
"    We suggest use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    for patients with frequent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe recurrences and for those with TNFR1-gene mutations that have been associated with a high risk of amyloidosis. Amyloidosis has been observed to respond to therapy with etanercept in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/16,27,28\">",
"     16,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If cost is not prohibitive,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    therapy may be appropriate for patients with less severe disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mutations that are less often associated with amyloidosis.",
"   </p>",
"   <p>",
"    Paradoxically, treatment with a different TNF antagonist (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , a monoclonal anti-TNF antibody) has been associated with flares of disease and is generally avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Anakinra",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with inadequate response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , the IL-1 receptor antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    can be highly effective, suggesting that IL-1 plays a central role in this disease, as it does in most autoinflammatory diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14854771\">",
"    <span class=\"h2\">",
"     Canakinumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41796?source=see_link\">",
"     Canakinumab",
"    </a>",
"    is a monoclonal antibody directed against IL-1&beta;. There is one case report of a patient successfully treated with canakinumab who had failed therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and had developed urticaria both on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    and on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28551/abstract/34\">",
"     34",
"    </a>",
"    ]. There is an ongoing phase 2 study of canakinumab in patients with TRAPS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TRAPS is a rare autosomal dominant autoinflammatory syndrome resulting from mutations in the TNF receptor (TNFRSF1A gene). Penetrance is variable. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical hallmarks include protracted febrile periods, focal myalgias, ocular involvement, and rash. Elevated inflammatory markers (ESR and CRP) are noted during and between episodes. Persistent inflammation may result in secondary amyloidosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of TRAPS may be suspected on the basis of the history, physical examination, and absence of an underlying infection, connective tissue disease, or neoplastic disorder. The diagnosis is confirmed by genetic testing for common mutations in the TNFR1 gene. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes all other causes of recurrent fevers, SLE, Still's disease, and other autoinflammatory diseases. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical experience suggests that, while fever may respond to use of NSAIDs, glucocorticoids are required to resolve other clinical manifestations of an attack. For patients with an established diagnosis of TRAPS and a typical attack, we suggest use of an oral glucocorticoid (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A typical agent is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (initial dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      followed by a gradual taper and discontinuation after 7 to 10 days). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Antiinflammatory drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preventing recurrent attacks and reducing the risk of developing amyloidosis are goals of therapy. We suggest use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      for patients with frequent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe recurrences and for those with TNFR1-gene mutations that have been associated with a high risk of amyloidosis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If cost is not prohibitive, etanercept therapy may be appropriate for patients with less severe disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mutations that are less often associated with amyloidosis. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Anti-TNF therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IL-1 antagonism may have a role in treatment of patients who have recurrent attacks despite use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Anakinra'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14854771\">",
"       'Canakinumab'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/1\">",
"      Hull KM, Drewe E, Aksentijevich I, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002; 81:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/2\">",
"      Yilmaz E, Ozen S, Balci B, et al. Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 2001; 9:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/3\">",
"      Simon A, van der Meer JW, Vesely R, et al. Approach to genetic analysis in the diagnosis of hereditary autoinflammatory syndromes. Rheumatology (Oxford) 2006; 45:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/4\">",
"      Williamson LM, Hull D, Mehta R, et al. Familial Hibernian fever. Q J Med 1982; 51:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/5\">",
"      Mulley J, Saar K, Hewitt G, et al. Gene localization for an autosomal dominant familial periodic fever to 12p13. Am J Hum Genet 1998; 62:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/6\">",
"      Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967; 43:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/7\">",
"      Ryan JG, Aksentijevich I. Tumor necrosis factor receptor-associated periodic syndrome: toward a molecular understanding of the systemic autoinflammatory diseases. Arthritis Rheum 2009; 60:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/8\">",
"      Nedjai B, Hitman GA, Yousaf N, et al. Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/9\">",
"      D'Osualdo A, Ferlito F, Prigione I, et al. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum 2006; 54:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/10\">",
"      Siebert S, Amos N, Fielding CA, et al. Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant. Arthritis Rheum 2005; 52:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/11\">",
"      Rebelo SL, Amel-Kashipaz MR, Radford PM, et al. Novel markers of inflammation identified in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) by transcriptomic analysis of effects of TRAPS-associated tumor necrosis factor receptor type I mutations in an endothelial cell line. Arthritis Rheum 2009; 60:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/12\">",
"      Lobito AA, Kimberley FC, Muppidi JR, et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006; 108:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/13\">",
"      Simon A, Park H, Maddipati R, et al. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci U S A 2010; 107:9801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/14\">",
"      Bulua AC, Simon A, Maddipati R, et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 2011; 208:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/15\">",
"      McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/16\">",
"      Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005; 17:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/17\">",
"      Dod&eacute; C, Andr&eacute; M, Bienvenu T, et al. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2002; 46:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/18\">",
"      Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/19\">",
"      Cantarini L, Lucherini OM, Brucato A, et al. Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin Res Cardiol 2012; 101:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/20\">",
"      Aksentijevich I, Galon J, Soares M, et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001; 69:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/21\">",
"      Kallinich T, Haffner D, Rudolph B, et al. \"Periodic fever\" without fever: two cases of non-febrile TRAPS with mutations in the TNFRSF1A gene presenting with episodes of inflammation or monosymptomatic amyloidosis. Ann Rheum Dis 2006; 65:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/22\">",
"      van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005; 5:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/23\">",
"      Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 1997; 90:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/24\">",
"      Gattorno M, Sormani MP, D'Osualdo A, et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum 2008; 58:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/25\">",
"      Drewe E, McDermott EM, Powell PT, et al. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford) 2003; 42:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/26\">",
"      Bulua AC, Mogul DB, Aksentijevich I, et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum 2012; 64:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/27\">",
"      Drewe E, Huggins ML, Morgan AG, et al. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 2004; 43:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/28\">",
"      Kallinich T, Briese S, Roesler J, et al. Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis. J Rheumatol 2004; 31:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/29\">",
"      Jacobelli S, Andr&eacute; M, Alexandra JF, et al. Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS). Rheumatology (Oxford) 2007; 46:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/30\">",
"      Nedjai B, Hitman GA, Quillinan N, et al. Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2009; 60:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/31\">",
"      Simon A, Bodar EJ, van der Hilst JC, et al. Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med 2004; 117:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/32\">",
"      Sacr&eacute; K, Brihaye B, Lidove O, et al. Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. J Rheumatol 2008; 35:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/33\">",
"      Gattorno M, Pelagatti MA, Meini A, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28551/abstract/34\">",
"      Brizi MG, Galeazzi M, Lucherini OM, et al. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. Ann Intern Med 2012; 156:907.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5580 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_56_28551=[""].join("\n");
var outline_f27_56_28551=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Recurrent fevers due to bacterial and other infectious and neoplastic causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Connective tissue diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other autoinflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Hyper-IgD syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - PFAPA syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Cyclic neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Anti-TNF therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Anakinra",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14854771\">",
"      Canakinumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31927?source=related_link\">",
"      Approach to the adult with fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9706?source=related_link\">",
"      Approach to the child with fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/3/11320?source=related_link\">",
"      Clinical manifestations and diagnosis of adult Still's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=related_link\">",
"      Clinical manifestations and diagnosis of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=related_link\">",
"      Cyclic neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3768?source=related_link\">",
"      Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3992?source=related_link\">",
"      Overview of autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=related_link\">",
"      Periodic fever syndromes and other autoinflammatory diseases: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8377?source=related_link\">",
"      Periodic fever with aphthous stomatitis, pharyngitis and adenitis (PFAPA syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_56_28552="Diagnostic approach to the adult presenting with neutropenic fever";
var content_f27_56_28552=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic approach to the adult presenting with neutropenic fever",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/56/28552/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/56/28552/contributors\">",
"     John R Wingard, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/56/28552/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/56/28552/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/56/28552/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/56/28552/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/56/28552/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H29410331\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever occurs frequently in patients with chemotherapy-induced neutropenia. Factors that contribute to the pathogenesis of neutropenic fever include the direct effects of chemotherapy on mucosal barriers and immune deficits related to the underlying malignancy. Prior to the era of empiric antibiotic therapy, infections accounted for most episodes of neutropenic fever and approximately 70 percent of the mortality in neutropenic acute leukemia patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/1\">",
"     1",
"    </a>",
"    ]. Because of the routine use of prompt empiric antibiotics, infections are documented less frequently today.",
"   </p>",
"   <p>",
"    Although the majority of patients with neutropenic fever do not have a documented infection, consensus guidelines recommend that all patients with neutropenic fever be promptly evaluated and treated with empiric broad-spectrum antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/2\">",
"     2",
"    </a>",
"    ]. This approach is indicated since it is difficult to distinguish life-threatening infections from less serious infections in this patient population, and infection may progress rapidly in such patients. Furthermore, better outcomes are seen with prompt therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic evaluation of patients presenting with neutropenic fever will be reviewed here. An overview of neutropenic fever syndromes as well as the risk assessment and management of patients with neutropenic fever are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=see_link\">",
"     \"Risk assessment of adults with chemotherapy-induced neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=see_link\">",
"     \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H270480452\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines have been developed for the evaluation and management of fever in neutropenic patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. The recommendations below are generally in keeping with the 2010 Infectious Diseases Society of America (IDSA) guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/2\">",
"     2",
"    </a>",
"    ]. These and other IDSA guidelines can be accessed through the",
"    <a class=\"external\" href=\"file://www.idsociety.org/IDSA_Practice_Guidelines/\">",
"     IDSA&rsquo;s web site",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29410338\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133182693\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever in neutropenic patients is defined as a single oral temperature of &gt;38.3&deg;C (101&deg;F) or a temperature of &gt;38.0&deg;C (100.4&deg;F) sustained for &gt;1 hour [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/2\">",
"     2",
"    </a>",
"    ]. The definition of fever is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link&amp;anchor=H278237232#H278237232\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Fever'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133182700\">",
"    <span class=\"h2\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of neutropenia varies from institution to institution but neutropenia is usually defined as an absolute neutrophil count (ANC) &lt;1500",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    and severe neutropenia is usually defined as an ANC &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    or an ANC that is expected to decrease to &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    over the next 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. The risk of clinically important infection rises as the neutrophil count falls below 500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and is higher in those with a prolonged duration of neutropenia (&gt;7 days). For the purposes of this discussion,",
"    <strong>",
"     we will define neutropenia as an ANC &lt;500",
"     <span class=\"nowrap\">",
"      cells/microL.",
"     </span>",
"    </strong>",
"   </p>",
"   <p>",
"    The ANC can be calculated by multiplying the total white blood cell (WBC) count by the percentage of polymorphonuclear cells (PMNs) and bands (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link&amp;anchor=H981551211#H981551211\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Neutropenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessment of the risk of neutropenia before the WBC and differential results are available is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link&amp;anchor=H154973874#H154973874\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\", section on 'Risk of neutropenia'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1035842267\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteremia is documented in only 10 to 25 percent of neutropenic fever episodes, and clinically documented infections are found in 20 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/2\">",
"     2",
"    </a>",
"    ]. Most documented infections during neutropenia are due to bacteria. Although gram-negative organisms predominated a few decades ago, most documented infections are now due to gram-positive organisms. Factors contributing to this trend include use of long-term central venous catheters and empiric and prophylactic antimicrobials that are primarily active against gram-negative pathogens. Fungi and viruses can also be pathogens, particularly in high-risk patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link&amp;anchor=H9533703#H9533703\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29410387\">",
"    <span class=\"h1\">",
"     PATIENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all cancer patients presenting with neutropenic fever, empiric antibacterial therapy should be initiated immediately after blood cultures have been obtained and before any other investigations have been completed. (See",
"    <a class=\"local\" href=\"#H222193074\">",
"     'Initiation of empiric therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    All patients should undergo a careful history and detailed physical examination, as well as laboratory, microbiology, and imaging studies; the approach to the diagnostic evaluation is summarized in the following Table (",
"    <a class=\"graphic graphic_table graphicRef50509 \" href=\"UTD.htm?23/55/24444\">",
"     table 1",
"    </a>",
"    ). Because symptoms and signs of infection are attenuated due to the lack of an inflammatory reaction, fever may be the sole sign of infection. Thus, it is important to recognize that the absence of the typical symptoms, signs, or laboratory findings suggestive of infection typically seen in non-neutropenic patients cannot be used to exclude the possibility of infection. The evaluation should be performed promptly",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29410394\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should probe for the development of new symptoms that can lead to identification of a site of infection. The initial clinical evaluation also focuses on assessing the risk of serious complications. (See",
"    <a class=\"local\" href=\"#H222192868\">",
"     'Risk assessment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following key elements of the history should always be included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inquire about organ-specific symptoms. A review of systems should be repeated daily. Determine if antimicrobial prophylaxis had been given and which agent(s).",
"     </li>",
"     <li>",
"      Probe for a history of prior infection or colonization (especially by antibiotic-resistant organisms).",
"     </li>",
"     <li>",
"      Determine if there might be non-infectious causes of fever (eg, blood transfusion, uncontrolled cancer).",
"     </li>",
"     <li>",
"      Determine which comorbid conditions may be present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222192868\">",
"    <span class=\"h2\">",
"     Risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial clinical evaluation focuses on assessing the risk of serious complications. This risk assessment dictates the approach to therapy, including the need for inpatient admission, IV antibiotics, and prolonged hospitalization (",
"    <a class=\"graphic graphic_table graphicRef67027 \" href=\"UTD.htm?39/26/40364\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Low-risk patients are defined as those who are expected to be neutropenic (absolute neutrophil count [ANC] &lt;500",
"       <span class=\"nowrap\">",
"        cells/microL)",
"       </span>",
"       for &le;7 days and those with no comorbidities or evidence of significant hepatic or renal dysfunction.",
"      </strong>",
"      This group of patients has been well studied in randomized trials and has been shown to be at low risk for serious complications [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/2\">",
"       2",
"      </a>",
"      ]. Most patients receiving chemotherapy for solid tumors are considered to be low-risk for complications requiring hospitalization or prolonging hospitalization.",
"     </li>",
"     <li>",
"      <strong>",
"       We define high-risk patients as those who are expected to be neutropenic (ANC &lt;500",
"       <span class=\"nowrap\">",
"        cells/microL)",
"       </span>",
"       for &gt;7 days. Patients with neutropenic fever who have ongoing comorbidities or evidence of significant hepatic or renal dysfunction are also considered to be high-risk, regardless of the duration of neutropenia.",
"      </strong>",
"      Other criteria that confer a high-risk status can be found in the Table (",
"      <a class=\"graphic graphic_table graphicRef67027 \" href=\"UTD.htm?39/26/40364\">",
"       table 2",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Some experts have defined high-risk patients as those expected to have profound neutropenia (ANC &le;100",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      for &gt;7 days based on experience that such patients are the most likely to have life-threatening complications [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/2,4\">",
"       2,4",
"      </a>",
"      ]. However, formal studies to clearly differentiate between patients with an ANC &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      and &le;100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      are lacking. For the purposes of this discourse, we will combine these groups. Profound prolonged neutropenia (ie, ANC &le;100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      expected to last &gt;7 days) is most likely to occur in the preengraftment phase of hematopoietic cell transplantation (particularly allogeneic) and in patients undergoing induction chemotherapy for acute leukemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An alternative to using the clinical criteria described above is to use the Multinational Association for Supportive Care in Cancer (MASCC) risk index, which is a validated tool for measuring the risk for neutropenic fever-related medical complications (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?14/34/14881?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk assessment of patients with neutropenic fever is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=see_link\">",
"     \"Risk assessment of adults with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29410402\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough general physical examination should be performed. The emphasis should be on sites most likely to be infected, including the skin, catheter sites, biopsy and bone marrow aspirate sites, teeth, oropharynx and gingival surfaces, sinuses, lungs, abdomen, genitals, and perianal area. As noted above, it is important to remember that in the absence of neutrophils, signs of inflammation can be extremely subtle.",
"   </p>",
"   <p>",
"    Review of systems and a physical examination should be repeated daily. In patients with persistent fever, new sites of infection (eg, lungs, skin, and urinary tract) may become apparent over time. In addition, as the neutrophil count recovers, localizing symptoms and signs of infection often become evident for the first time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H588437531\">",
"    <span class=\"h3\">",
"     Lungs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lungs are a common site of infection in patients with chemotherapy-induced neutropenia and should be examined for signs of pneumonia (eg, crackles). Hypoxia, tachypnea, and increased work of breathing are other signs of pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H588437539\">",
"    <span class=\"h3\">",
"     Abdomen",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abdominal examination should be performed to evaluate for peritoneal signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abdominal tenderness, which may represent neutropenic enterocolitis or Clostridium difficile colitis. Even when an abdominal process is present, abdominal signs may be subtle or absent in neutropenic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27125?source=see_link\">",
"     \"Typhlitis (neutropenic enterocolitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H588437524\">",
"    <span class=\"h3\">",
"     Intravenous catheter sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;All intravenous (IV) catheter sites, especially central venous catheter sites, should be carefully examined for subtle signs of infection; slight erythema or tenderness may be the only evidence of a serious \"tunnel\" infection. Fluctuance or exudates are unlikely since the lack of inflammatory cells inhibits the development of inflammatory reactions. IV catheters should also be assessed for any malfunction; difficulty with infusion or blood drawing can also be a sign of an infected venous thrombosis, even in the absence of a problem with the exit site. Sites of recent IV catheters should also be examined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H588437504\">",
"    <span class=\"h3\">",
"     Skin and mucous membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin and mucous membranes should be examined for signs of erythema, rash, cellulitis, ulcers, furuncles, vesicles, paronychia, mucositis, dental or peritonsillar cellulitis, perianal fissures, and pilonidal disease. Skin lesions can often be a manifestation of a systemic infection including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Ulcers",
"      </strong>",
"      &ndash; Fungi, atypical bacteria, nontuberculous mycobacteria, viruses",
"     </li>",
"     <li>",
"      <strong>",
"       Vesicles",
"      </strong>",
"      &ndash; Viruses",
"     </li>",
"     <li>",
"      <strong>",
"       Nodules",
"      </strong>",
"      &ndash; Fungi, bacteria, nontuberculous mycobacteria",
"     </li>",
"     <li>",
"      <strong>",
"       Ecthyma gangrenosum",
"      </strong>",
"      &ndash; Large lesion with a necrotic center that is classically seen with Pseudomonas aeruginosa but also with other bacteria, such as Staphylococcus aureus (",
"      <a class=\"graphic graphic_picture graphicRef80582 \" href=\"UTD.htm?26/43/27314\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Skin lesions with a necrotic center",
"      </strong>",
"      &ndash; Invasive fungal infections (eg, Fusarium spp, Aspergillus spp, Mucorales) can also cause skin lesions with a necrotic center (",
"      <a class=\"graphic graphic_picture graphicRef57016 \" href=\"UTD.htm?3/49/3858\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef64575 \" href=\"UTD.htm?5/43/5809\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sometimes, skin lesions, such as erythema multiforme, can be related to viral infections; alternatively, erythema multiforme can be related to antibiotic therapy and may be associated with fever, causing diagnostic confusion (",
"    <a class=\"graphic graphic_picture graphicRef74095 \" href=\"UTD.htm?40/61/41951\">",
"     picture 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infections that can cause fever and rash in immunocompromised hosts are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/34/42537?source=see_link\">",
"     \"Infectious causes of fever and rash in non-HIV immunocompromised hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H588437511\">",
"    <span class=\"h3\">",
"     Perianal region",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examination should also include inspection of the perianal area. Erythema, pain on palpation, and tender hemorrhoids are important signs of infection. However, digital rectal examination (and rectal temperatures) should be avoided so that one does not introduce infection by traumatizing the fragile mucosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24668186\">",
"    <span class=\"h2\">",
"     Routine laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation should include a complete blood cell count with differential, hepatic transaminases, bilirubin, electrolytes, serum creatinine, blood urea nitrogen, urinalysis, and cultures (",
"    <a class=\"graphic graphic_table graphicRef50509 \" href=\"UTD.htm?23/55/24444\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In interpreting laboratory results in neutropenic patients, it is important to recognize that the absence of the typical laboratory findings suggestive of infection that are usually seen in non-neutropenic patients cannot be used to exclude the possibility of infection. Therefore, absence of abnormalities, such as cerebrospinal fluid pleocytosis, pyuria, or neutrophils on sputum Gram stain, does not rule out infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24668193\">",
"    <span class=\"h2\">",
"     Serum fungal markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Checking fungal markers from the serum, such as the Aspergillus galactomannan antigen and the beta-D-glucan assay, should also be considered in high-risk patients. Some centers perform serial monitoring of these twice weekly in hematopoietic cell transplant recipients and acute leukemia patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/2\">",
"     2",
"    </a>",
"    ]. The Aspergillus galactomannan antigen is a specific test for invasive aspergillosis, whereas the beta-D-glucan assay is a nonspecific test for several invasive fungal infections, including aspergillosis and candidiasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link&amp;anchor=H1064486430#H1064486430\">",
"     \"Diagnosis of invasive aspergillosis\", section on 'Galactomannan antigen detection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link&amp;anchor=H1064486465#H1064486465\">",
"     \"Diagnosis of invasive aspergillosis\", section on 'Beta-D-glucan assay'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29410416\">",
"    <span class=\"h2\">",
"     Microbiology and other diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all cancer patients presenting with neutropenic fever, empiric antibacterial therapy should be initiated immediately after blood cultures have been obtained and before any other investigations have been completed. The microbiologic evaluation should be performed promptly. (See",
"    <a class=\"local\" href=\"#H222193074\">",
"     'Initiation of empiric therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Specimens for the microbiology laboratory should include at least two sets of blood cultures (",
"    <a class=\"graphic graphic_table graphicRef50509 \" href=\"UTD.htm?23/55/24444\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/2\">",
"     2",
"    </a>",
"    ]. Each set should have a volume of 20 mL (proportionally smaller volume in children weighing &lt;40 kg; eg, no more than 1 percent of estimated patient total blood volume). In patients with a central venous catheter (CVC), we prefer to collect a set of blood cultures simultaneously from each lumen and from a peripheral vein site. Some experts feel that it is acceptable to collect both sets of cultures from the CVC, especially in patients with difficult peripheral venous access. In patients without a CVC, a set should be obtained from each of two separate venipuncture sites. The diagnosis of CVC infections is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis of intravascular catheter-related infections\", section on 'Blood cultures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two sets of blood cultures are typically repeated daily for persistent fevers or rigors at least during the first two days following initiation of empiric antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/2\">",
"     2",
"    </a>",
"    ]. Institutions may have different guidelines for the frequency of obtaining blood cultures. As an example, some centers stop collecting blood cultures or reduce the frequency of collection after several days if the initial cultures are negative for patients with a stable fever pattern. If the cultures are positive, they should be repeated until they become negative to ensure response to therapy, and intermittently thereafter.",
"   </p>",
"   <p>",
"    Specimens should be obtained from other sites as clinically indicated (eg, sputum, urine, CVC exit site, cerebrospinal fluid, skin, stool). Many neutropenic patients receiving cytotoxic chemotherapy are also thrombocytopenic; in such patients, platelet transfusions are often necessary in order to safely perform a lumbar puncture or other invasive procedures. In general, indications for collection of these additional samples are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Stool",
"      </strong>",
"      &ndash; If diarrhea is present, send a Clostridium difficile toxin assay. There is limited utility in sending stool samples for culture or ova and parasites in hospitalized patients in the United States; these studies can be sent in patients with recent travel to or residence in areas that are endemic for enteric pathogens, or if there is another reason to suspect an enteric pathogen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link&amp;anchor=H15443523#H15443523\">",
"       \"Clostridium difficile in adults: Clinical manifestations and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Urine",
"      </strong>",
"      &ndash; If symptoms of urinary tract infection are present, send urine for bacterial culture and susceptibility testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24214?source=see_link\">",
"       \"Urine sampling and culture in the diagnosis of urinary tract infection in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Skin",
"      </strong>",
"      &ndash; If skin lesions are present, aspirate or biopsy for bacterial and fungal stains and cultures and, if vesicles are present, for herpes simplex and varicella-zoster virus stains and cultures and direct fluorescent antibody testing. When a biopsy is obtained, it should also be sent for histopathology. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link&amp;anchor=H25#H25\">",
"       \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/4/77?source=see_link\">",
"       \"Diagnosis of varicella-zoster virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Respiratory",
"      </strong>",
"      &ndash; If productive cough is present, send sputum for bacterial and fungal stains and cultures and assays for respiratory viruses [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"       \"Diagnostic approach to community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Neutropenic patients with pulmonary infiltrates often cannot produce sputum; a more invasive approach, including bronchoscopy with bronchoalveolar lavage (",
"      <a class=\"graphic graphic_table graphicRef70685 \" href=\"UTD.htm?28/8/28813\">",
"       table 3",
"      </a>",
"      ) or video-assisted thoracoscopic surgery, may need to be pursued in order to make a microbiologic diagnosis. This may be particularly important for patients with infiltrates on chest radiographs or chest computed tomography (CT) who continue to worsen despite 24 to 48 hours of empiric antibiotic therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"       \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cerebrospinal fluid (CSF)",
"      </strong>",
"      &ndash; If symptoms of meningitis (fever, headache, nuchal rigidity, altered mental status), are present, send CSF for cell count, glucose, protein, and bacterial culture and susceptibility testing. In addition, in patients with clinical signs of meningitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      encephalitis, CSF should also be sent for cryptococcal antigen testing and for polymerase chain reaction testing for herpes simplex virus, cytomegalovirus, varicella-zoster virus, and, in allogeneic hematopoietic cell transplant recipients, human herpes virus 6. Additional tests are indicated if epidemiologic risk factors are present (eg, testing for West Nile virus, Eastern equine encephalitis, and other arthropod-borne encephalitides during the summer in certain regions). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in adults\", section on 'Lumbar puncture'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15417?source=see_link\">",
"       \"Aseptic meningitis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=see_link&amp;anchor=H14#H14\">",
"       \"Herpes simplex virus type 1 encephalitis\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=see_link\">",
"       \"Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=see_link\">",
"       \"Arthropod-borne encephalitides\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=see_link\">",
"       \"Diagnosis of cytomegalovirus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30346?source=see_link&amp;anchor=H665911236#H665911236\">",
"       \"Human herpesvirus 6 infection in hematopoietic cell transplant recipients\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29410423\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies should be performed promptly, but should not delay initiation of empiric therapy. (See",
"    <a class=\"local\" href=\"#H222193074\">",
"     'Initiation of empiric therapy'",
"    </a>",
"    below.)",
"    <br/>",
"    <br/>",
"    In febrile neutropenic patients with respiratory signs or symptoms, we suggest that a chest x-ray be obtained in low-risk patients and a chest CT be obtained in high-risk patients (see",
"    <a class=\"local\" href=\"#H222192868\">",
"     'Risk assessment'",
"    </a>",
"    above). In contrast, the IDSA guidelines recommend a chest x-ray as part of the initial evaluation for neutropenic fever in patients with respiratory symptoms without distinction by risk status [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/2\">",
"     2",
"    </a>",
"    ]. It is important to note, however, that chest x-ray findings are often minimal or absent, even in patients with pneumonia or pulmonary nodules. Chest CT is much more sensitive for detecting abnormalities in neutropenic patients.",
"   </p>",
"   <p>",
"    In one study, high-resolution chest CT demonstrated pneumonia in more than one-half of persistently febrile neutropenic patients who had normal findings on routine chest x-ray [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/10\">",
"     10",
"    </a>",
"    ]. It was estimated that high-resolution CT scanning resulted in the diagnosis being established five days earlier compared with the exclusive use of chest x-rays, but did not improve clinical outcomes. Although CT scanning has not been shown to change clinical outcomes, one should have a low threshold for ordering a CT scan in both high- and low-risk neutropenic patients with pulmonary symptoms to help guide the selection and duration of treatment, and to assess for radiographic evidence of invasive fungal disease. Repeat chest imaging should be obtained for increasing or persistent pulmonary symptoms and signs, including cough, shortness of breath,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/2\">",
"     2",
"    </a>",
"    ]. Radiographic findings may become evident along with an increase in symptoms as the neutropenia begins to resolve.",
"   </p>",
"   <p>",
"    CT scanning of other sites (head, sinuses,",
"    <span class=\"nowrap\">",
"     abdomen/pelvis)",
"    </span>",
"    should be performed according to suggestive symptoms or other risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/2\">",
"     2",
"    </a>",
"    ]. In particular, patients with neutropenic fever and any signs or symptoms suggestive of neutropenic enterocolitis or Clostridium difficile colitis (eg, abdominal pain or tenderness, diarrhea) should undergo abdominal CT scanning with IV and oral contrast. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27125?source=see_link&amp;anchor=H5#H5\">",
"     \"Typhlitis (neutropenic enterocolitis)\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222193074\">",
"    <span class=\"h1\">",
"     INITIATION OF EMPIRIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever in a neutropenic patient should be considered a medical emergency. Early studies documented mortality rates of up to 70 percent if initiation of antibiotics was delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/11\">",
"     11",
"    </a>",
"    ]. Therefore, the evaluation of such patients should occur promptly and broad-spectrum antibiotics should be given as soon as possible and at full doses (adjusted for renal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatic function). In all cancer patients presenting with neutropenic fever, empiric antibacterial therapy should be initiated immediately after blood cultures have been obtained and before any other investigations have been completed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link&amp;anchor=H24660640#H24660640\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Timing of antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The aim of empiric therapy is to cover the most likely and most virulent pathogens that may rapidly cause serious or life-threatening infection in neutropenic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/2\">",
"     2",
"    </a>",
"    ]. Empiric therapy approaches are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29410444\">",
"    <span class=\"h1\">",
"     EVALUATION OF PERSISTENT OR RECURRENT FEVER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent or recurrent fever should prompt a thorough search for a source of occult infection. Repeat cultures of blood and other cultures or diagnostic tests should be performed on the basis of symptoms and signs. Diarrhea should be evaluated with a Clostridium difficile toxin assay.",
"   </p>",
"   <p>",
"    Repeating",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    broadening the imaging evaluation is warranted for persistent or recurrent fever. An abdominal computed tomography (CT) scan should be considered to evaluate for neutropenic enterocolitis when abdominal signs are present (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27125?source=see_link\">",
"     \"Typhlitis (neutropenic enterocolitis)\"",
"    </a>",
"    ). CT scans of the chest and sinuses are useful to evaluate for occult mold infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link\">",
"     \"Mucormycosis (zygomycosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management algorithms have been developed for the reassessment of neutropenic patients with persistent fever after two to four days (",
"    <a class=\"graphic graphic_algorithm graphicRef74452 \" href=\"UTD.htm?0/14/225\">",
"     algorithm 1",
"    </a>",
"    ), and after four or more days (",
"    <a class=\"graphic graphic_algorithm graphicRef53163 \" href=\"UTD.htm?11/47/12017\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28552/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link&amp;anchor=H423440041#H423440041\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\", section on 'Persistent fever'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29410451\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever during chemotherapy-induced neutropenia is a medical emergency requiring prompt evaluation and treatment. Fever in neutropenic patients is defined as a single oral temperature of &gt;38.3&deg;C (101.0&deg;F) or a temperature of &gt;38.0&deg;C (100.4&deg;F) sustained for &gt;1 hour. We define neutropenia as an absolute neutrophil count &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H29410331\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H133182693\">",
"       'Fever'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H133182700\">",
"       'Neutropenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In all cancer patients presenting with neutropenic fever, empiric antibacterial therapy should be initiated immediately after blood cultures have been obtained and before any other investigations have been completed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"       \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"       \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacteremia is documented in only 10 to 25 percent of neutropenic fever episodes, and clinically documented infections are found in 20 to 30 percent. Most documented infections during neutropenia are due to gram-positive organisms. Fungi and viruses can also be pathogens, particularly in high-risk patients. (See",
"      <a class=\"local\" href=\"#H1035842267\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic evaluation should include a targeted history, physical examination, and laboratory assessments (",
"      <a class=\"graphic graphic_table graphicRef50509 \" href=\"UTD.htm?23/55/24444\">",
"       table 1",
"      </a>",
"      ). This includes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Blood cultures and cultures obtained from other suspected sites of infection",
"     </li>",
"     <li>",
"      Chest imaging &mdash; In febrile neutropenic patients with respiratory signs or symptoms, we suggest that a chest x-ray be obtained in low-risk patients and a chest computed tomography (CT) scan be obtained in high-risk patients.",
"     </li>",
"     <li>",
"      Abdominal imaging &mdash; Patients with neutropenic fever and any signs or symptoms suggestive of neutropenic enterocolitis or Clostridium difficile colitis (eg, abdominal pain or tenderness, diarrhea) should undergo abdominal CT scanning. (See",
"      <a class=\"local\" href=\"#H29410387\">",
"       'Patient evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent or recurrent fever should prompt a thorough search for a source of occult infection. Repeat cultures of blood and other cultures or diagnostic tests should be performed on the basis of symptoms and signs. Management algorithms have been developed for the reassessment of neutropenic patients with persistent fever after two to four days (",
"      <a class=\"graphic graphic_algorithm graphicRef74452 \" href=\"UTD.htm?0/14/225\">",
"       algorithm 1",
"      </a>",
"      ), and after four or more days (",
"      <a class=\"graphic graphic_algorithm graphicRef53163 \" href=\"UTD.htm?11/47/12017\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29410444\">",
"       'Evaluation of persistent or recurrent fever'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29410459\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGEMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We would like to acknowledge Dr. Gregory K Robbins who contributed to earlier versions of this topic review.",
"    <br/>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28552/abstract/1\">",
"      HERSH EM, BODEY GP, NIES BA, FREIREICH EJ. CAUSES OF DEATH IN ACUTE LEUKEMIA: A TEN-YEAR STUDY OF 414 PATIENTS FROM 1954-1963. JAMA 1965; 193:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28552/abstract/2\">",
"      Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28552/abstract/3\">",
"      Zuckermann J, Moreira LB, Stoll P, et al. Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes. Ann Hematol 2008; 87:139.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 1.2012. file://www.nccn.org (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28552/abstract/5\">",
"      Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31:794.",
"     </a>",
"    </li>",
"    <li>",
"     Standards, practice guidelines, and statements developed and/or endorsed by IDSA. file://www.idsociety.org/Content.aspx?id=9088 (Accessed on December 02, 2011).",
"    </li>",
"    <li>",
"     US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed on February 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28552/abstract/8\">",
"      Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28552/abstract/9\">",
"      Hirsch HH, Martino R, Ward KN, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis 2013; 56:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28552/abstract/10\">",
"      Heussel CP, Kauczor HU, Heussel GE, et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol 1999; 17:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28552/abstract/11\">",
"      Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 284:1061.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16139 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-07C1274D5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_56_28552=[""].join("\n");
var outline_f27_56_28552=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29410451\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29410331\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H270480452\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29410338\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H133182693\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H133182700\">",
"      Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1035842267\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29410387\">",
"      PATIENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29410394\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H222192868\">",
"      Risk assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29410402\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H588437531\">",
"      - Lungs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H588437539\">",
"      - Abdomen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H588437524\">",
"      - Intravenous catheter sites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H588437504\">",
"      - Skin and mucous membranes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H588437511\">",
"      - Perianal region",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24668186\">",
"      Routine laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24668193\">",
"      Serum fungal markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29410416\">",
"      Microbiology and other diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29410423\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H222193074\">",
"      INITIATION OF EMPIRIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29410444\">",
"      EVALUATION OF PERSISTENT OR RECURRENT FEVER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29410451\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29410459\">",
"      ACKNOWLEDGEMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/16139\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16139|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?0/14/225\" title=\"algorithm 1\">",
"      Neutropenic fever reassessment after 2 to 4 days",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/47/12017\" title=\"algorithm 2\">",
"      Fever neutropenia reassessment after four days",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16139|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/43/27314\" title=\"picture 1\">",
"      Ecthyma gangrenosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/49/3858\" title=\"picture 2\">",
"      Necrotic skin lesion of mucormycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/43/5809\" title=\"picture 3\">",
"      Fusarium skin lesions on lower extremities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/61/41951\" title=\"picture 4\">",
"      Erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16139|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/55/24444\" title=\"table 1\">",
"      Diagnostic evaluation fever and neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/26/40364\" title=\"table 2\">",
"      High-risk patients with neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/8/28813\" title=\"table 3\">",
"      BAL studies in immunocompromised hosts with pneumonia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=related_link\" title=\"calculator 1\">",
"      Calculator: Absolute neutrophil count",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?14/34/14881?source=related_link\" title=\"calculator 2\">",
"      Calculator: Multinational Association for Supportive Care in Cancer (MASCC) risk index for patients with neutropenic fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=related_link\">",
"      Arthropod-borne encephalitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15417?source=related_link\">",
"      Aseptic meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=related_link\">",
"      Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=related_link\">",
"      Diagnosis of cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=related_link\">",
"      Diagnosis of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=related_link\">",
"      Diagnosis of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/77?source=related_link\">",
"      Diagnosis of varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=related_link\">",
"      Herpes simplex virus type 1 encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30346?source=related_link\">",
"      Human herpesvirus 6 infection in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/34/42537?source=related_link\">",
"      Infectious causes of fever and rash in non-HIV immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=related_link\">",
"      Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adults with hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=related_link\">",
"      Risk assessment of adults with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27125?source=related_link\">",
"      Typhlitis (neutropenic enterocolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24214?source=related_link\">",
"      Urine sampling and culture in the diagnosis of urinary tract infection in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_56_28553="Ferning of cervical mucus";
var content_f27_56_28553=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Ferning of cervical mucus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Ferning of cervical mucus.",
"    <br>",
"     (B) A ferning pattern of cervical mucus occurs with high estrogen levels.",
"     <br>",
"      (C) Incomplete ferning during secretory phase of cycle.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from:",
"       <br>",
"        (A) Lexikon Medizin, 3rd Edition. Munich, Germany: Urban &amp; Schwarzenburg, 1993.",
"        <br>",
"         (B) Scott JR. Danforth's Obstetrics and Gynecology, 6th Edition. Philadelphia: J.B. Lippincott, 1990.",
"         <br>",
"          (C) Scott JR. Danforth's Obstetrics and Gynecology, 6th Edition. Philadelphia: J.B. Lippincott, 1990.",
"         </br>",
"        </br>",
"       </br>",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_56_28553=[""].join("\n");
var outline_f27_56_28553=null;
var title_f27_56_28554="Prognosis and treatment of polycythemia vera";
var content_f27_56_28554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prognosis and treatment of polycythemia vera",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/56/28554/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/56/28554/contributors\">",
"     Ayalew Tefferi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/56/28554/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/56/28554/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/56/28554/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/56/28554/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/56/28554/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycythemia vera (PV) is one of the myeloproliferative neoplasms, which are collectively characterized by clonal proliferation of myeloid cells with variable morphologic maturity and hematopoietic efficiency (",
"    <a class=\"graphic graphic_figure graphicRef56283 \" href=\"UTD.htm?24/16/24835\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/1\">",
"     1",
"    </a>",
"    ]. PV is distinguished clinically from the other myeloproliferative neoplasms by the presence of an elevated red blood cell mass (RCM, also called erythrocytosis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link\">",
"     \"Overview of the myeloproliferative neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the prognosis and treatment of polycythemia vera [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Approaches to the patient with suspected polycythemia vera or polycythemia in general are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link\">",
"     \"Diagnostic approach to the patient with suspected polycythemia vera\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24777?source=see_link\">",
"     \"Diagnostic approach to the patient with polycythemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median survival of",
"    <strong>",
"     untreated",
"    </strong>",
"    symptomatic patients with PV was initially estimated at 6 to 18 months from the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/5\">",
"     5",
"    </a>",
"    ], whereas current survival of",
"    <strong>",
"     treated",
"    </strong>",
"    patients is 10 years or more (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/6\">",
"     6",
"    </a>",
"    ]. The overall mortality in treated patients is 1.6 to 1.7 times that of an age- and sex-matched normal population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In a large multinational prospective study of 1638 patients, the overall mortality rate was 3.7 deaths per 100",
"    <span class=\"nowrap\">",
"     persons/year",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/9\">",
"     9",
"    </a>",
"    ]. Cardiovascular mortality, solid tumors, and hematologic transformation accounted for 45, 20, and 13 percent of the deaths, respectively.",
"   </p>",
"   <p>",
"    Other prospective data were obtained from the Polycythemia Vera Study Group (PVSG) major protocol of over 400 patients, all of whom were treated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/10\">",
"     10",
"    </a>",
"    ]. The median survival varied from 9.1 to 12.6 years with different therapies. The most common causes of death were thrombosis (29 percent), hematologic malignancies (23 percent), nonhematologic malignancies (16 percent), hemorrhage (7 percent), and",
"    <span class=\"nowrap\">",
"     myelofibrosis/myeloid",
"    </span>",
"    metaplasia (3 percent).",
"   </p>",
"   <p>",
"    A long-term study using registry date from two well-defined cohorts evaluated prognostic risk factors for survival and leukemia in 327 PV patients. At a median follow-up of 11 years, the following observations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median age at diagnosis was 71 years (range: 21 to 95), while the median age at death was 81 years. Death was attributed to thrombotic events, secondary acute myeloid leukemia (AML), solid tumors, and chronic heart failure in 21, 17, 17, and 15 percent, respectively.",
"     </li>",
"     <li>",
"      Median survivals for those &lt;65 or &ge;65 years at the time of diagnosis were 17.5 and 6.5 years, respectively. Relative survival, that focused on deaths directly attributable to PV, was 93, 72, and 46 percent, respectively, after 5, 10, and 20 years of disease duration.",
"     </li>",
"     <li>",
"      On multivariate analysis, age &gt;70 years, white blood cell count",
"      <span class=\"nowrap\">",
"       &gt;13,000/microL",
"      </span>",
"      (&gt;13 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L),",
"      </span>",
"      and thrombosis at diagnosis were significant predictors of survival. Relative survivals were 84, 59, and 26 percent for those with none, one, or two to three of these risk factors at the time of PV diagnosis, respectively.",
"     </li>",
"     <li>",
"      Transformation to AML occurred in 30 subjects (22 females, 8 males, 9.2 percent) at a median time of 55.4 months (range: 27 to 262 months) after diagnosis of PV. All but two had received treatment with myelosuppressive agents.",
"     </li>",
"     <li>",
"      Secondary myelofibrosis developed in 37 subjects (11.5 percent), with a cumulative risk of 6, 14, and 26 percent after 10, 15, and 20 years, respectively. No significant risk factors for transformation to myelofibrosis were identified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Preliminary data on survival and prognosis from a larger international study of 1263 patients with PV identified advanced age, leukocytosis, history of venous thrombosis, and abnormal karyotype as significant risk factors for reduced overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/12\">",
"     12",
"    </a>",
"    ]. A risk score based on age (&ge;70 years: 3 points; 60 to 69 years: 2 points) and leukocyte count",
"    <span class=\"nowrap\">",
"     &ge;15,000/microL",
"    </span>",
"    (one point) yielded overall survivals of 27, 17, 11, and 8 years for those with scores of zero, one to two, three, or four, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Thrombotic events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival in PV is compromised primarily as the result of increased whole blood viscosity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/5,7,10,13\">",
"     5,7,10,13",
"    </a>",
"    ], with its attendant decrease in cerebral blood flow and high incidence of fatal thrombotic complications, including myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. In some but not all studies, leukocytosis has been suggested as an adverse risk factor for vascular events in both PV and ET, although the mechanisms involved are unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32202?source=see_link&amp;anchor=H4#H4\">",
"     \"Prognosis and treatment of essential thrombocythemia\", section on 'Risk factors for thrombosis and hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two large studies of patients with PV, age over 65 to 70, and a history of previous thrombosis were the most powerful predictors of recurrent thrombosis and cardiovascular events [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/7,9\">",
"       7,9",
"      </a>",
"      ]. The annual incidence of thrombosis ranged from 1.8 percent in patients below age 40 to 5.1 percent in those over 70 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/7\">",
"       7",
"      </a>",
"      ]. The latter figure (5.1 percent) is similar to the annual stroke risk of a 75-year-old person with atrial fibrillation and a prior thromboembolic event (5.3 percent) or to the annual cardiovascular risk of a 75-year-old smoker with hypertension and diabetes (5.6 percent).",
"     </li>",
"     <li>",
"      In a Mayo Clinic series of 459 patients, multivariate analysis identified arterial thrombosis at the time of diagnosis, age &ge;60, and a total white blood cell count",
"      <span class=\"nowrap\">",
"       &gt;15,000/microL",
"      </span>",
"      as independent predictors of inferior survival [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/18\">",
"       18",
"      </a>",
"      ]. A risk stratification model based on age and white blood cell count criteria alone indicated median survivals of 23, 14, and 9 years for subjects with none, one, or both of these adverse features, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although one study found an incidence of vascular occlusive episodes 1.5 times higher in patients with PV and a platelet count above",
"    <span class=\"nowrap\">",
"     400,000/microL,",
"    </span>",
"    neither the degree of thrombocytosis nor the presence of platelet function abnormalities has been consistently correlated with thrombotic risk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/10,15,21\">",
"     10,15,21",
"    </a>",
"    ]. Similarly, the role of cardiovascular risk factors in the occurrence of thrombosis is disputed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hematologic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major cause of death in PV is disease transformation into post-PV myelofibrosis (post-PV MF)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    evolution into acute myeloid",
"    <span class=\"nowrap\">",
"     leukemia/myelodysplastic",
"    </span>",
"    syndrome",
"    <span class=\"nowrap\">",
"     (AML/MDS)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/7,10,22,23\">",
"     7,10,22,23",
"    </a>",
"    ]. In the large multinational prospective study of 1638 patients noted above, the rate of such hematologic transformation was 1.3 episodes per 100 patient-years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/9\">",
"     9",
"    </a>",
"    ]. This risk is approximately 1000 times that of myelofibrosis in the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of primary myelofibrosis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Myelofibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the multinational study mentioned above, the only significant risk factor for development of post-PV MF was disease duration, with relative risks of 5.7 and 15.2 for durations of &gt;6 and &gt;10 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/9\">",
"     9",
"    </a>",
"    ]. In our Mayo Clinic series, the only risk factor identified was age &ge;60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/18\">",
"     18",
"    </a>",
"    ], while an Italian study suggested that a total white blood cell count",
"    <span class=\"nowrap\">",
"     &gt;15,000/microL",
"    </span>",
"    at the time of diagnosis of PV was a significant risk factor for development of post-PV MF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In this Italian study of 647 patients with PV, median survival of the 68 patients (10 percent) who developed post-PV MF was 5.7 years. Using multivariate analysis, adverse risk factors for survival at any time after the onset of post-PV MF included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemoglobin &lt;10.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      White blood cell count",
"      <span class=\"nowrap\">",
"       &gt;30,000/microL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Median survivals for those who ultimately developed none, one, two, or all three of these adverse risk factors were &gt;108, 51, 15, and 3 months, respectively.",
"   </p>",
"   <p>",
"    Although not well studied in a prospective controlled fashion, a number of other factors have been reported to be associated with a higher risk for development of post-PV MF. These include homozygosity for the JAK2 mutation (increased allele burden), presence of endogenous megakaryocyte colony formation in vitro, and elevated serum levels of lactate dehydrogenase [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/25-29\">",
"     25-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Acute leukemia/MDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two reports, age &gt;70 (relative risk 4.3 to 5.0, depending on the analysis performed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/9,30\">",
"     9,30",
"    </a>",
"    ]) and use of cytoreductive agents other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    and interferon at the time of recruitment (relative risk 5.5 to 11.0) were the only factors significantly associated with the development of acute",
"    <span class=\"nowrap\">",
"     leukemia/MDS.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=see_link&amp;anchor=H6#H6\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\", section on 'Cytotoxic agents that have been implicated'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our Mayo Clinic series, only leukocytosis was identified as an adverse risk factor on multivariate analysis, although the incidence of leukemia was found to increase according to the treatment given, as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No cytoreductive therapy (or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/19/6454?source=see_link\">",
"       anagrelide",
"      </a>",
"      , interferon) &mdash; 2.4 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       Hydroxyurea",
"      </a>",
"      (with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/19/6454?source=see_link\">",
"       anagrelide",
"      </a>",
"      , interferon) &mdash; 4 percent",
"     </li>",
"     <li>",
"      Single agent cytotoxic agent other than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      &mdash; 12 percent",
"     </li>",
"     <li>",
"      Two or more cytotoxic agents &mdash; 17 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once developed, the prognosis for acute leukemia in all of the",
"    <span class=\"nowrap\">",
"     BCR/ABL-negative",
"    </span>",
"    myeloproliferative neoplasms (ie, polycythemia vera, essential thrombocythemia, primary myelofibrosis) is dismal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. In one report of 74 such patients, median survival was five months from the time of blastic transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/33\">",
"     33",
"    </a>",
"    ]. Complete remissions were noted in about one-half of the patients receiving induction chemotherapy. However, remissions were not durable, with a median progression-free survival of five months. Long-term survival was seen only in patients who received allogeneic hematopoietic cell transplantation either as initial therapy or during first remission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16722283\">",
"    <span class=\"h3\">",
"     Chronic myeloid leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clonal evolution of PV to chronic myeloid leukemia (CML) is a rare phenomenon, occurring either when a stem cell carrying the JAK2 mutation acquires the",
"    <em>",
"     BCR-ABL1",
"    </em>",
"    translocation, or when PV and CML have evolved from separate clones [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/34-37\">",
"     34-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     THERAPEUTIC TRIALS IN PV",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     The major PVSG trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the major therapeutic goals of the Polycythemia Vera Study Group (PVSG) was the prevention of thrombosis by means of phlebotomy with or without concomitant myelosuppressive therapy. The therapeutic dilemma in PV prior to the founding of the PVSG was the trade-off between potentially fatal early thrombotic events in patients treated with phlebotomy alone versus the late occurrence of myelofibrosis and secondary malignancies, especially acute myeloid leukemia, in those treated with myelosuppressive agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    and radioactive phosphate (",
"    <sup>",
"     32",
"    </sup>",
"    P) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an effort to solve this dilemma, the Polycythemia Vera Study Group initiated a prospective trial, randomly assigning patients with PV to treatment with one of the following three arms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Phlebotomy alone to keep the hematocrit below 52 percent, or",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       Chlorambucil",
"      </a>",
"      , with supplemental phlebotomy as needed for a HCT &gt;52 percent, or",
"     </li>",
"     <li>",
"      Radioactive phosphate (",
"      <sup>",
"       32",
"      </sup>",
"      P), with supplemental phlebotomy (as for the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      arm)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The protocol was subsequently modified to require maintenance of a hematocrit of 45 percent or less in each of the treatment arms. The reason for this change is discussed below. (See",
"    <a class=\"local\" href=\"#H8323402\">",
"     'The optimal hematocrit in PV'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Over 400 patients were accrued to this study, which began in 1967. Complete follow-up was available in 1987, at which time the longest follow-up for randomized patients was approximately 18 years. At the time of the 1987 follow-up, 51 percent of the patients in the initially randomized cohort had died. As noted above, the most common causes of death were thrombosis (29 percent), hematologic malignancies (23 percent), nonhematologic malignancies (16 percent), hemorrhage (7 percent), and post-PV MF (3 percent). Median survival was 9, 11, and 13 years for patients randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <sup>",
"     32",
"    </sup>",
"    P, or phlebotomy, respectively. These differences were statistically significant, with the major benefit occurring after seven years (",
"    <a class=\"graphic graphic_figure graphicRef79644 \" href=\"UTD.htm?33/35/34365\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of thrombosis in the first two years of treatment was 23 percent in patients randomly assigned to treatment with phlebotomy alone, significantly higher than that in the",
"    <sup>",
"     32",
"    </sup>",
"    P treatment arm (16 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. Cerebrovascular accident, deep vein thrombosis, myocardial infarction, and peripheral arterial occlusion represented 35, 22, 12, and 9 percent of all on study thrombotic events, respectively. The increased frequency of thrombosis in patients randomly assigned to receive phlebotomy alone continued for the first three years of treatment; the subsequent incidence of thrombotic events was similar in the three treatment arms after the first three years (",
"    <a class=\"graphic graphic_figure graphicRef59865 \" href=\"UTD.htm?40/37/41565\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Secondary malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ultimate incidence of acute myeloid leukemia (AML) in the main PVSG study was 1.5, 10, and 13 percent for phlebotomy,",
"    <sup>",
"     32",
"    </sup>",
"    P, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    treatment, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/10\">",
"     10",
"    </a>",
"    ]. At an interim analysis at a median follow-up of more than 6.5 years, the risk of acute leukemia in patients given chlorambucil was 2.3 times that in patients receiving",
"    <sup>",
"     32",
"    </sup>",
"    P and 13 times that in patients treated with phlebotomy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/39\">",
"     39",
"    </a>",
"    ]. All remaining study patients receiving chlorambucil were switched to treatment with phlebotomy alone at that time; no further treatment protocols utilizing an alkylating agent were carried out by the PVSG after that time.",
"   </p>",
"   <p>",
"    The incidence of gastrointestinal and skin cancers was also higher in the two myelosuppressive treatment arms (4, 9, and 12 percent, respectively). Other solid tumors (chiefly genitourinary, breast, and lung) occurred with similar frequency in the three arms (about 6 percent). Of interest, 3.5 percent of the patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    developed non-Hodgkin lymphoma, a complication that was not seen in any patient in the other two treatment arms (",
"    <a class=\"graphic graphic_figure graphicRef67138 \" href=\"UTD.htm?41/47/42749\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Post-PV myelofibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of post-PV MF was approximately 10 percent in all three treatment arms. The presence of post-PV MF, as contrasted with its absence, significantly increased the incidence of acute leukemia (0.8 versus 7.1 percent, 10 versus 28 percent, and 11 versus 36 percent), for patients without and with post-PV MF in the phlebotomy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    and",
"    <sup>",
"     32",
"    </sup>",
"    P treatment arms, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conclusions were drawn from the PVSG major trial:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Phlebotomy treatment yielded the best overall survival, but at the cost of increased thrombotic events during the first three years.",
"     </li>",
"     <li>",
"      Myelosuppressive therapy reduced the incidence of thrombosis, but increased the risk of acute leukemia, lymphoma, gastrointestinal, and skin malignancies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Subsequent PVSG protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two approaches to these problems were taken by the PVSG: an attempt to reduce the incidence of thrombosis by adding high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    to the phlebotomy arm, and an efficacy trial of the antimetabolite",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    in the hope that it would be less leukemogenic than either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    or",
"    <sup>",
"     32",
"    </sup>",
"    P.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Phlebotomy plus aspirin and dipyridamole",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial comparing the \"best\" myelosuppressive arm (",
"    <sup>",
"     32",
"    </sup>",
"    P, 2.7",
"    <span class=\"nowrap\">",
"     mCi/m2",
"    </span>",
"    IV, limit 5",
"    <span class=\"nowrap\">",
"     mCi/dose)",
"    </span>",
"    versus phlebotomy plus \"high dose\"",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (300 mg orally three times per day) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    (75 mg orally three times per day) was begun in 1977 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/10\">",
"     10",
"    </a>",
"    ]. After initial phlebotomy to an HCT of 40 percent or less, treatment was begun. Phlebotomy was subsequently performed in both arms to keep the HCT in the range of 40 to 45 percent.",
"   </p>",
"   <p>",
"    The incidence of thrombosis in the phlebotomy-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    arm was 16 percent in the first two years, compared with 5 percent in the",
"    <sup>",
"     32",
"    </sup>",
"    P arm. The addition of aspirin and dipyridamole to phlebotomy increased the risk of gastrointestinal bleeding, especially in those patients with platelet counts",
"    <span class=\"nowrap\">",
"     &gt;930,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/41\">",
"     41",
"    </a>",
"    ]. The combined incidence of treatment failure (ie, death, thrombosis, hemorrhage) on the aspirin-dipyridamole arm was eight times higher than among patients treated with",
"    <sup>",
"     32",
"    </sup>",
"    P. Multivariate analysis did not uncover any significant risk factor to account for this result, other than the initial randomization event.",
"   </p>",
"   <p>",
"    Accordingly, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in these &ldquo;high&rdquo; doses (ie, 300 mg orally three times daily), with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , is no longer recommended as treatment for polycythemia vera. The use of &ldquo;low dose&rdquo; aspirin (ie, 40 to 100 mg PO once per day) in this condition is discussed below (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Low-dose aspirin'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a subsequent PVSG phase II trial, 51 patients with PV were given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    (HU, 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for one week, followed by 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day thereafter), in order to maintain a platelet count",
"    <span class=\"nowrap\">",
"     &lt;600,000/microL",
"    </span>",
"    and the hematocrit below 50 percent, using minimal phlebotomy treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/10,42\">",
"     10,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with HU was, in the first two years, associated with a 9 percent incidence of thrombosis, a value significantly lower than that seen in the phlebotomy arm (23 percent) or the",
"    <sup>",
"     32",
"    </sup>",
"    P arm (16 percent) of the major PVSG trial or the phlebotomy-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    (PAD) arm of the second PVSG trial of PAD versus",
"    <sup>",
"     32",
"    </sup>",
"    P (16 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After a mean follow-up period of 8.6 years, the incidence of acute leukemia in the HU efficacy trial was 6 percent, higher than that seen in the phlebotomy arm of the main PVSG study (1.5 percent), although this difference was not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/10,42\">",
"     10,42",
"    </a>",
"    ]. However, with the addition of patients who subsequently developed myelodysplasia (MDS), the incidence of",
"    <span class=\"nowrap\">",
"     AML/MDS",
"    </span>",
"    rose to 8 percent, a level that did reach statistical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In other trials, the incidence of leukemic conversion in PV, when HU is used alone, has ranged from 1 to 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/9,43-48\">",
"     9,43-48",
"    </a>",
"    ], with the lower values obtained at shorter follow-up times. This is consistent with the observation that at least 50 percent of the cases of acute myeloid leukemia in patients with PV occur after six years of treatment with myelosuppressive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/40\">",
"     40",
"    </a>",
"    ]. In addition, several studies of patients with myeloproliferative neoplasms have suggested a further increase in leukemia risk when HU is combined with other agents, with rates approaching 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/47,49-52\">",
"     47,49-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been concluded by many groups that HU is definitely leukemogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/53\">",
"     53",
"    </a>",
"    ], while other groups, including our own, are not convinced. In one study, for example, peripheral blood mononuclear cells from patients with myeloproliferative neoplasms and prolonged exposure to HU did not show increased DNA mutations when compared with those having low exposure to HU or to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hydroxyurea versus pipobroman",
"    </span>",
"    &nbsp;&mdash;&nbsp;A French cooperative study randomly assigned 292 patients with PV under the age of 65 to treatment with HU or pipobroman. They noted an incidence of AML of 10 percent in both arms at a mean follow-up period of 13 years, similar to that noted by the PVSG for the HU arm, and significantly higher than that noted following phlebotomy alone (1.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At a median follow-up of 16.3 years, the following results were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Median survival was significantly longer for those treated on the HU arm than the pipobroman arm (20.3 versus 15.4 years); both treatment groups had significantly shorter survival than the general population.",
"     </li>",
"     <li>",
"      At the time of evaluation, 95 patients had died (33 percent of the initial cohort). The major causes of death were evolution to",
"      <span class=\"nowrap\">",
"       AML/MDS",
"      </span>",
"      (54 percent), vascular events (15 percent), and solid tumor development (12 percent).",
"     </li>",
"     <li>",
"      The cumulative incidence of",
"      <span class=\"nowrap\">",
"       AML/MDS",
"      </span>",
"      at 10, 15, and 20 years was significantly lower in the HU arm (6.6, 16.5, and 24 percent, respectively) than in the pipobroman arm (13, 34, and 52 percent, respectively).",
"     </li>",
"     <li>",
"      The cumulative incidence of myelofibrosis at 10, 15, and 20 years was significantly higher in the HU arm (15, 24, and 32 percent, respectively) than in the pipobroman arm (5, 10, and 21 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that pipobroman was leukemogenic and unsuitable for first-line therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Interferon alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, control of erythrocytosis occurs in approximately 80 percent of patients receiving subcutaneous interferon alpha (IFNa) in doses ranging from 4.5 to 27 million units per week (usual dose: 3 million units subcutaneously three times per week) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]. A similar degree of benefit was appreciated in terms of reduction in spleen size and relief from intractable pruritus in another series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/59\">",
"     59",
"    </a>",
"    ]. However, up to 35 percent of patients have discontinued IFNa therapy because of intolerable side effects such as fever, malaise, nausea, and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/58,60-62\">",
"     58,60-62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Pegylated interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports of efficacy with reduced toxicity have been observed with the use of pegylated interferon alpha-2a, which also provides prolonged activity compatible with once weekly dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/63-65\">",
"     63-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one phase II study of pegylated interferon-alfa-2a (initial dose: 90",
"      <span class=\"nowrap\">",
"       mcg/week",
"      </span>",
"      subcutaneously for the first 2 weeks, increased as tolerated to a maximal dose of 180",
"      <span class=\"nowrap\">",
"       micrograms/week),",
"      </span>",
"      35 of 37 evaluable patients achieved complete hematologic remission with 7 of the 35 achieving molecular complete remission (ie, JAK2 V617F mutation undetectable) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/66\">",
"       66",
"      </a>",
"      ]. Responses were durable; 35 patients remained in hematologic CR at one year. Only three patients stopped treatment during the first year because of side effects.",
"     </li>",
"     <li>",
"      Similar results were achieved in a second trial in 40 patients with advanced PV [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/67\">",
"       67",
"      </a>",
"      ]. The planned dose (450",
"      <span class=\"nowrap\">",
"       mcg/week)",
"      </span>",
"      was poorly tolerated, and most were controlled on 45 to 90",
"      <span class=\"nowrap\">",
"       mcg/week",
"      </span>",
"      with grade 1 or 2 toxicity. Overall hematologic response rate was 80 percent, while overall and complete molecular response rates for the 38 subjects with the JAK2 V617F mutation were 54 and 14 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results from nonrandomized long-term studies suggest a possible advantage with IFNa compared with phlebotomy or phlebotomy plus HU in terms of better control of splenomegaly, thrombocytosis, pruritus, and thrombohemorrhagic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/62,68,69\">",
"     62,68,69",
"    </a>",
"    ]. The ability of IFNa to suppress clonal hematopoiesis in chronic myeloid leukemia and reports of cytogenetic and molecular remissions in PV suggest a potentially exploitable biological effect with this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/66,70-72\">",
"     66,70-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared with HU, IFNa is more expensive and less well tolerated. A prospective, randomized evaluation of pegylated IFNa versus HU has been initiated by the MPD Research Consortium in order to determine the place of IFNa preparations in the treatment of high-risk PV patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8323402\">",
"    <span class=\"h2\">",
"     The optimal hematocrit in PV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal hematocrit in PV is not known with certainty. The following retrospective studies are of interest in this regard:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small study of 16 patients, low cerebral blood flow was found at hematocrits greater than 46 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/74\">",
"       74",
"      </a>",
"      ]. Lowering the hematocrit by phlebotomy from a mean level of 53.6 percent to a mean level of 45.5 percent resulted in a 73 percent increase in mean cerebral blood flow and a 30 percent reduction in whole blood viscosity.",
"     </li>",
"     <li>",
"      In a retrospective review in patients with PV treated with phlebotomy with or without chemotherapy, there was a positive correlation between vascular occlusive episodes and hematocrit, with a suggested optimum hematocrit of less than 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a matched pair analysis of patients experiencing a thrombotic event on the PVSG-01 major protocol, neither the hematocrit nor the platelet count showed significant correlation with thrombotic risk, although the number of patients with hematocrits above 52 percent was small [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a multivariate analysis of a prospective study involving 1638 patients with PV, a hematocrit in the range of 40 to 55 percent was associated with neither thrombotic events nor mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This question was addressed in a prospective randomized trial in 365 adults with JAK2-positive PV who were being treated with phlebotomy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , or both. Subjects were randomly assigned to either more intensive treatment (target hematocrit &lt;45 percent) or less intensive treatment (target hematocrit 45 to 50 percent). After a median follow-up of 31 months, the following results were reported on an intent-to-treat analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/77\">",
"     77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary end point, time until death from cardiovascular causes or major thrombotic events, was recorded in 5 of 182 patients in the lower hematocrit group (2.7 percent) and 18 of 183 patients in the higher hematocrit group (9.8 percent). The hazard ratio for the higher hematocrit group was 3.91 (95% CI 1.45-10.5).",
"     </li>",
"     <li>",
"      The rates of adverse events (ie, progression to myelofibrosis or myelodysplasia, leukemic transformation, bleeding) were not significantly different between the two treatment groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result of the above studies, we and various authors have suggested that the hematocrit be maintained at less than 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/2,77,78\">",
"     2,77,78",
"    </a>",
"    ], or at less than 45 percent in men and less than 42 percent in women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the increase in plasma volume during pregnancy and in patients with an enlarged spleen, a normal hematocrit in some patients with PV may mask an expanded red cell mass [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/80\">",
"     80",
"    </a>",
"    ]. The European LeukemiaNet has suggested that the target hematocrit in the pregnant woman with PV should be either &lt;45 percent or the normal midgestation hematocrit range (&lt;40 percent), whichever is lower [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Anagrelide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/19/6454?source=see_link\">",
"     Anagrelide",
"    </a>",
"    , a quinazoline derivative, was initially developed as a platelet function inhibitor and then noted to be a relatively selective thrombocytopenic agent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/81\">",
"     81",
"    </a>",
"    ]. The mechanism by which anagrelide reduces platelet count is not yet clear, although the current hypothesis is that anagrelide affects the late (postmitotic) phases of megakaryocyte development.",
"   </p>",
"   <p>",
"    The recommended starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    is 0.5 mg four times a day or 1 mg twice a day, with dose adjustment to the lowest effective amount (usual maximum daily dose of 4",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    required to reduce and maintain the platelet count to less than",
"    <span class=\"nowrap\">",
"     600,000/microL.",
"    </span>",
"    Adverse effects of this agent include fluid retention, vasodilation with renal insufficiency, and frank heart failure.",
"   </p>",
"   <p>",
"    In one study, 577 patients, 73 percent of whom had been previously treated unsuccessfully with other modalities, were given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/19/6454?source=see_link\">",
"     anagrelide",
"    </a>",
"    to control the thrombocytosis of chronic myeloproliferative disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/82\">",
"     82",
"    </a>",
"    ]. Three hundred thirty-five patients had primary thrombocythemia, 114 chronic myeloid leukemia, 68 polycythemia vera, and 60 undifferentiated myeloproliferative diseases. Anagrelide reduced the platelet count by 50 percent or to less than",
"    <span class=\"nowrap\">",
"     600,000/microL",
"    </span>",
"    for at least 28 days in 93 percent of evaluable patients. Acquired resistance to the drug was not observed, but 16 percent of patients discontinued treatment because of side effects. Long-term efficacy and safety of this medication have yet to be shown.",
"   </p>",
"   <p>",
"    Additional information on the toxicity of this agent in PV and ET can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32202?source=see_link&amp;anchor=H13#H13\">",
"     \"Prognosis and treatment of essential thrombocythemia\", section on 'Anagrelide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Low-dose aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;&ldquo;High-dose&rdquo;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (eg, 300 mg three times per day) in PV had been discouraged because of the previously demonstrated association with an increased incidence of gastrointestinal hemorrhage in a prior PVSG trial (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Phlebotomy plus aspirin and dipyridamole'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/41\">",
"     41",
"    </a>",
"    ]. However, there may be a particular advantage of low-dose aspirin in PV. Thromboxane biosynthesis is elevated in this disorder and the in vivo activity is suppressible with low-dose aspirin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/83\">",
"     83",
"    </a>",
"    ]. These observations, along with those described below, suggest that low-dose aspirin might be safe and possibly effective in preventing thrombosis in PV [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A pilot study performed by the Gruppo Italiano Studio Policitemia Vera randomly assigned 112 PV patients to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo; low-dose aspirin was well tolerated, without increased bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/85\">",
"     85",
"    </a>",
"    ]. As a result, the effectiveness of low-dose aspirin in reducing the incidence of thrombosis in PV was planned to be tested in approximately 1800 patients over a five-year follow-up period in a multicenter double-blind randomized European trial (ECLAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/86\">",
"     86",
"    </a>",
"    ]. Patients with PV and no clear indication (eg, history of thrombosis) or contraindication to aspirin treatment were to be randomly assigned to receive aspirin (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo, with additional aims of maintaining the hematocrit at &le;45 percent in all subjects and the platelet count below",
"    <span class=\"nowrap\">",
"     400,000/microliter",
"    </span>",
"    in patients over 50 years of age, using standard cytoreductive treatment.",
"   </p>",
"   <p>",
"    Because of poor enrollment, accrual to the study was stopped early and follow-up was confined to a period of 12 months, resulting in a small number of cardiovascular and bleeding events. In addition, base-line characteristics of the enrolled patients indicated that the study suffered from inadequate lowering of the hematocrit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/87\">",
"     87",
"    </a>",
"    ]. Given the limitations of this study, the following results were obtained in 518 evaluable patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/88\">",
"     88",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      significantly lowered the combined risk of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, or major venous thrombosis (relative risk 0.40, 95% CI: 0.18-0.91).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      significantly reduced the combined rate of major or minor thrombosis (relative risk 0.42, 95% CI: 0.24-0.74).",
"     </li>",
"     <li>",
"      The study was insufficiently powered to detect significant differences between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and placebo in the rates of any bleeding, major bleeding, or minor bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A Cochrane analysis of these two reports [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/85,88\">",
"     85,88",
"    </a>",
"    ], covering 630 PV patients, concluded that the use of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (compared with placebo) was associated with a non-significant lower risk of fatal thrombotic events (OR 0.20; 95% CI 0.03-1.1) and did not increase the risk of major bleeding (OR 0.99; 95% CI 0.23-4.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results of this study did not support a predictive value of hematocrit for death or thrombotic events in these patients, in whom the hematocrit level was maintained below 45 percent in only half of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/76\">",
"     76",
"    </a>",
"    ]. Similarly, there was no association between platelet count and thrombotic events in these patients, in whom the platelet count was maintained below",
"    <span class=\"nowrap\">",
"     300,000/microL",
"    </span>",
"    in only 36 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Imatinib mesylate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of the tyrosine kinase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    mesylate (Gleevec) has been reported in a number of patients with PV. In most of the reports response has been limited to a reduction in phlebotomy requirement and a reduction in the size of the spleen; it has been ineffective in controlling thrombocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/90-93\">",
"     90-93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical patient with a new diagnosis of PV is symptomatic, with such complaints as a prior or current thrombotic or hemorrhagic event, headache, weakness, dizziness, epigastric distress, and pruritus. Worrisome physical and laboratory findings may include hypertension, symptomatic gout, tender splenomegaly, and a high hematocrit, white blood cell count, and platelet count. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnostic approach to the patient with suspected polycythemia vera\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goals of treatment are to minimize these clinical, physical, and laboratory features while also minimizing the long-term complications of the disease (eg, thrombotic events, bleeding, myelofibrosis, acute leukemia, other malignancies) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/94\">",
"     94",
"    </a>",
"    ]. This has not been easy to accomplish; as outlined below, a number of the long-term complications of PV (eg, thrombosis, secondary malignancy) may be exacerbated by the type of treatment selected.",
"   </p>",
"   <p>",
"    Based primarily upon the observations of the PVSG, the mainstay of therapy in PV remains phlebotomy to keep the hematocrit below 45 percent in men and 42 percent in women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/95-97\">",
"     95-97",
"    </a>",
"    ]. Since phlebotomy is effective in controlling polycythemia by producing a state of relative or absolute iron deficiency, iron supplementation should",
"    <strong>",
"     not",
"    </strong>",
"    be given.",
"   </p>",
"   <p>",
"    For special groups, our approach consists of [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/38,78,98,99\">",
"     38,78,98,99",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supplement phlebotomy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      (starting dose 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) (",
"      <a class=\"graphic graphic_table graphicRef63410 \" href=\"UTD.htm?39/0/39947\">",
"       table 1",
"      </a>",
"      ) in patients who are at high-risk for thrombosis (age &gt;60, prior thrombosis). Since it takes at least three to five days for the effect of this agent to be seen, dose adjustments should not be made more frequently than once per week. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32202?source=see_link&amp;anchor=H10#H10\">",
"       \"Prognosis and treatment of essential thrombocythemia\", section on 'Hydroxyurea'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If not otherwise contraindicated because of a history of major bleeding or intolerance,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      should be given to all patients in a low dose of 75 to 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/86,88,98\">",
"       86,88,98",
"      </a>",
"      ]. Treatment with higher doses should be avoided.",
"     </li>",
"     <li>",
"      Although the use of radioactive",
"      <sup>",
"       32",
"      </sup>",
"      P (starting dose 2.5",
"      <span class=\"nowrap\">",
"       mCi/m2",
"      </span>",
"      IV not more often than every 12 weeks) is discouraged in young patients because of its leukemogenicity, this agent may have a role in patients who cannot follow any treatment program that requires frequent visits, as well as in those whose life expectancy is less than 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/100\">",
"       100",
"      </a>",
"      ]. However, this agent is not available in many locations.",
"     </li>",
"     <li>",
"      It is reasonable to use IFNa in patients with refractory pruritus, in high-risk women of childbearing potential [",
"      <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/101\">",
"       101",
"      </a>",
"      ], and in the patient refractory to all other medications (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Interferon alpha'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       Allopurinol",
"      </a>",
"      (usual daily dose 300 mg) is given to patients with symptomatic hyperuricemia or urinary uric acid excretion above 1100",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      a level which carries a 50 percent risk of uric acid calculi. Allopurinol should not be started in patients with a history of gout until appropriate prophylaxis has been given. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link\">",
"       \"Prevention of recurrent gout\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of patients who develop secondary myelofibrosis is similar to that of patients with primary myelofibrosis and is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36922?source=see_link&amp;anchor=H9#H9\">",
"       \"Prognosis and treatment of primary myelofibrosis\", section on 'Specific treatments'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic complications are common in PV, and should be treated as in any other patient, with appropriate doses and intensity of anticoagulation. However, there are no randomized studies that might be helpful in determining how long anticoagulation should be continued in a patient with PV and a first episode of venous thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/102-104\">",
"     102-104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myelosuppressive agents should be employed if the platelet count is elevated at the time of the thrombotic event. The general goal is to return the platelet count to normal, although there are no randomized trials which have determined the &ldquo;optimal&rdquo; platelet count in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8180693\">",
"    <span class=\"h2\">",
"     Response to treatment with hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criteria of response to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    have been proposed by the European LeukemiaNet (ELN), as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete response  hematocrit &lt;45 percent without phlebotomy, platelet count",
"      <span class=\"nowrap\">",
"       &lt;400,000/microL,",
"      </span>",
"      white blood cell count",
"      <span class=\"nowrap\">",
"       &lt;10,000/microL,",
"      </span>",
"      normal spleen size on imaging, and absence of disease-related symptoms",
"     </li>",
"     <li>",
"      Partial response  absence of a complete response but achievement of a hematocrit &lt;45 percent without phlebotomy or a response in three or more of the other criteria listed immediately above",
"     </li>",
"     <li>",
"      Nonresponse  any response that did not satisfy the partial response criteria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a series of 261 patients with PV treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    for a median time of 4.4 years, complete, partial, and nonresponses were noted in 24, 66, and 10 percent, respectively. Fulfilling the ELN criteria for complete or partial response was not associated with a benefit in the clinical outcome in PV, whereas response in platelet and white blood cell counts were predictive of less thrombohemorrhagic complications and better prognosis, respectively. Resistance to treatment with hydroxyurea was an adverse prognostic factor, with a significantly higher risk of both death and disease transformation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding is commonly seen in PV, although major bleeding episodes are relatively rare. Such episodes may be associated with excessively high platelet counts, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in doses greater than 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the use of anticoagulants or antiplatelet agents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Acquired von Willebrand disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients with ET or PV and platelet counts &gt;1",
"    <span class=\"nowrap\">",
"     million/microL,",
"    </span>",
"    acquired von Willebrand disease may be present, likely due to increased binding of large VWF multimers to the platelets and their removal from the plasma. Such patients may have increased bleeding, especially when treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . Cytoreduction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    usually corrects both the clinical and laboratory abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link&amp;anchor=H13#H13\">",
"     \"Classification and pathophysiology of von Willebrand disease\", section on 'Acquired von Willebrand disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis and clinical manifestations of essential thrombocythemia\", section on 'Thrombosis and hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pruritus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritus occurs at some time during the course of PV in 40 to 50 percent of patients. It may be the symptom that first brings the patient to the physician, can be intolerable to the patient, and frustrating to treat. In the 93 patients with pruritus in our series, the symptom was severe enough to require treatment in 71 percent, and substantially interfered with the quality of life in 43 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since both the temperature of the water and vigorous rubbing of the skin are factors in post-bath pruritus, the patient should be told to reduce water temperature and to pat the skin dry rather than using vigorous rubbing. Starch baths (a half box of Linet starch in a tub of lukewarm water followed by gentle drying) may be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other treatments have included antihistamines, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/25/19862?source=see_link\">",
"     cyproheptadine",
"    </a>",
"    (4 mg three times daily), H2-receptor blockers, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    (300 mg four times daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/107-110\">",
"     107-110",
"    </a>",
"    ], photochemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/111,112\">",
"     111,112",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/113\">",
"     113",
"    </a>",
"    ], and interferon alfa [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/59\">",
"     59",
"    </a>",
"    ]. Occasional patients are refractory to all of these treatments, and require some form of myelosuppression for relief, which is often incomplete (see below).",
"   </p>",
"   <p>",
"    Based on anecdotal reports of benefit in pruritus associated with other conditions, we treated 10 patients with PV-associated refractory pruritus with the oral serotonin reuptake inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/105,114\">",
"     105,114",
"    </a>",
"    ]. All 10 experienced a favorable initial response, usually within 48 hours; complete or nearly complete resolution of pruritus occurred in eight. Eight patients have continued the medication for a period of 1 to 12 months, with reduction in efficacy in only one. Side effects were noted in three patients and included delayed ejaculation, decreased libido, and fatigue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Erythromelalgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythromelalgia is a pathognomonic microvascular complication of PV or essential thrombocythemia. It refers to burning pain in the feet or hands accompanied by erythema, pallor or cyanosis (",
"    <a class=\"graphic graphic_picture graphicRef81121 \" href=\"UTD.htm?17/25/17808\">",
"     picture 1",
"    </a>",
"    ), and occurs in patients with a platelet count above",
"    <span class=\"nowrap\">",
"     400,000/microL.",
"    </span>",
"    Observational studies have shown that erythromelalgia responds dramatically to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in low doses (eg, 50 to 100 mg per day) or to reduction of the platelet count to normal with low-dose myelosuppressive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/83,115,116\">",
"     83,115,116",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnostic approach to the patient with suspected polycythemia vera\", section on 'Erythromelalgia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited experience concerning the treatment of the pregnant woman with PV, given that this disorder is not often seen in women of childbearing years. Practical suggestions include keeping the hematocrit below 45 percent, the use of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    throughout pregnancy, and, if myelosuppression is required, the use of interferon, as employed in the related disorder, essential thrombocythemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/2,78\">",
"     2,78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32202?source=see_link&amp;anchor=H26#H26\">",
"     \"Prognosis and treatment of essential thrombocythemia\", section on 'Pregnant women or those who desire to become pregnant'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of prophylactic anticoagulation with low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH) for the first six weeks following delivery has been suggested for low-risk pregnant women with PV, while for those with a previous major thrombotic or bleeding complication or a previous severe pregnancy complication, the use of LMWH throughout pregnancy has been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/2,78,117\">",
"     2,78,117",
"    </a>",
"    ]. However, there are no data confirming the safety and utility of these prophylactic approaches in pregnant women with PV, and we do not recommend the use of LMWH unless there is evidence for active thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16772936\">",
"    <span class=\"h2\">",
"     Transformation to myelodysplasia or acute leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients who develop secondary myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) is similar to that of patients with primary MDS or AML, and is discussed separately. In one study in 21 patients with PV who developed MDS or AML and were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    (initial dose: 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    subcutaneously for 7 days every 28 days), the overall response rate was 33 percent, with a median survival of 7 months from the onset of treatment with this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/56/28554/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis for such patients with transformation to",
"    <span class=\"nowrap\">",
"     MDS/AML",
"    </span>",
"    is poor, as responses to treatment are generally worse in patients with prior PV than in those who develop MDS or AML de novo. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=see_link\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/14/12513?source=see_link\">",
"       \"Patient information: Polycythemia vera (PV) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7838225\">",
"    <span class=\"h2\">",
"     Prognosis and need for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median survival of",
"    <strong>",
"     untreated",
"    </strong>",
"    symptomatic patients with polycythemia vera (PV) is 6 to 18 months, whereas survival of treated patients is 10 years or more. Accordingly, all patients with symptomatic PV should be treated.",
"   </p>",
"   <p>",
"    The most common causes of death in PV are thrombosis, hematologic and nonhematologic malignancies, hemorrhage, and post-PV myelofibrosis. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7838342\">",
"    <span class=\"h2\">",
"     Overall treatment goals",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hematocrit control",
"      </strong>",
"      &mdash; In subjects without active thrombosis and those not at risk for thrombosis (ie, age &lt;60, no prior thrombosis), we recommend that the hematocrit be kept within the normal range via the use of serial phlebotomy, rather than by the use of myelosuppressive agents (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Optimal control is to keep the hematocrit below 45 percent in men and 42 percent in women. (See",
"      <a class=\"local\" href=\"#H8323402\">",
"       'The optimal hematocrit in PV'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment issues'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Since phlebotomy is effective in controlling PV by producing a state of relative or absolute iron deficiency, iron supplementation should not be given.",
"     </li>",
"     <li>",
"      <strong>",
"       Patients at high risk for thrombosis",
"      </strong>",
"      &mdash; For patients at high risk for thrombosis (ie, age &gt;60, prior thrombosis) we recommend that treatment with phlebotomy be supplemented with the use of a myelosuppressive agent. (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For this purpose we prefer the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      rather than an alkylating agent, radioactive",
"      <sup>",
"       32",
"      </sup>",
"      P, or interferon alpha. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Hydroxyurea'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      If not otherwise contraindicated because of a history of major bleeding or intolerance, we suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      be given to all patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The appropriate dose is 75 to 100",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      Treatment with higher doses should be avoided. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Low-dose aspirin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Alternative myelosuppressive agents",
"      </strong>",
"      &mdash; Although the use of radioactive",
"      <sup>",
"       32",
"      </sup>",
"      P is discouraged in young patients because of its leukemogenicity, we suggest the use of this agent, where available, in patients who cannot be evaluated on a regular, recurring basis, and in those whose life expectancy is less than 10 years (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest the use of interferon alpha (IFNa) in patients with refractory pruritus, in high-risk women of childbearing potential, and in the patient refractory to all other medications (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Interferon alpha'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Control of leukocytosis",
"      </strong>",
"      &mdash; There is not sufficient information in the literature to support the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      for low- or intermediate-risk patients with PV and leukocytosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7839177\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care in patients with PV includes control of severe itching (pruritus), hyperuricemia and gout, erythromelalgia, and bleeding.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Severe itching (pruritus)",
"      </strong>",
"      &mdash; Pruritus in patients with PV, especially post-bathing, is difficult to control. Suggested agents include antihistamines, H2-receptor blockers, serotonin reuptake inhibitors, interferon alpha, and in resistant cases, myelosuppression. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Pruritus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Hyperuricemia and acute gout",
"      </strong>",
"      &mdash; Treatment of hyperuricemia, excessive excretion of uric acid, or acute gout is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=see_link\">",
"       \"Asymptomatic hyperuricemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/24/17800?source=see_link\">",
"       \"Treatment of acute gout\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link\">",
"       \"Prevention of recurrent gout\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Erythromelalgia",
"      </strong>",
"      &mdash;",
"      <strong>",
"      </strong>",
"      We recommend that erythromelalgia (a burning pain in the feet or hands accompanied by erythema, pallor or cyanosis) be treated with low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Erythromelalgia unresponsive to treatment with low-dose aspirin should be treated with myelosuppression. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Erythromelalgia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Bleeding",
"      </strong>",
"      &mdash; Extraneous causes for bleeding (eg, use of high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , antiplatelet agents, anticoagulants) should be stopped. Patients should be evaluated for acquired von Willebrand disease and treated accordingly. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Bleeding'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7839163\">",
"    <span class=\"h2\">",
"     Development of myelofibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients who develop post-PV myelofibrosis is similar to that of patients with",
"    <strong>",
"    </strong>",
"    primary myelofibrosis and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36922?source=see_link&amp;anchor=H9#H9\">",
"     \"Prognosis and treatment of primary myelofibrosis\", section on 'Specific treatments'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7839170\">",
"    <span class=\"h2\">",
"     Development of myelodysplasia or acute leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients who develop secondary myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) is similar to that of patients with primary MDS or AML, and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link\">",
"     \"Treatment of acute myeloid leukemia in older adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=see_link\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=see_link\">",
"     \"Overview of the treatment of myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/1\">",
"      Damashek W. Some speculations on the myeloproliferative disorders. Blood 1951; 6:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/2\">",
"      Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/3\">",
"      Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/4\">",
"      Passamonti F. How I treat polycythemia vera. Blood 2012; 120:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/5\">",
"      CHIEVITZ E, THIEDE T. Complications and causes of death in polycythaemia vera. Acta Med Scand 1962; 172:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/6\">",
"      Berk PD, Goldberg JD, Donovan PB, et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986; 23:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/7\">",
"      Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med 1995; 123:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/8\">",
"      Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/9\">",
"      Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23:2224.",
"     </a>",
"    </li>",
"    <li>",
"     Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: A summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Polycythemia Vera and the Myeloproliferative Disorders, Wasserman LR, Berk PD, Berlin NI (Eds), WB Saunders, Philadelphia 1995. p.166.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/11\">",
"      Bonicelli G, Abdulkarim K, Mounier M, et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients. Br J Haematol 2013; 160:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/12\">",
"      Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1,263 patients with polycythemia vera: an international study. Blood 2011; 118:127. Abstract 277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/13\">",
"      LAWRENCE JH, BERLIN NI, HUFF RL. The nature and treatment of polycythemia; studies on 263 patients. Medicine (Baltimore) 1953; 32:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/14\">",
"      Wade JP. Transport of oxygen to the brain in patients with elevated haematocrit values before and after venesection. Brain 1983; 106 (Pt 2):513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/15\">",
"      Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978; 2:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/16\">",
"      Pearson TC, Wetherley-Mein G. The course and complications of idiopathic erythrocytosis. Clin Lab Haematol 1979; 1:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/17\">",
"      Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007; 109:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/18\">",
"      Gangat N, Strand J, Li CY, et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007; 138:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/19\">",
"      Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 2009; 114:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/20\">",
"      Gangat N, Wolanskyj AP, Schwager SM, et al. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer 2009; 115:5740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/21\">",
"      Ohyashiki K, Akahane D, Gotoh A, et al. Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status. Leukemia 2007; 21:2544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/22\">",
"      Rozman C, Giralt M, Feliu E, et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 67:2658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/23\">",
"      Fallah M, Kharazmi E, Sundquist J, Hemminki K. Higher risk of primary cancers after polycythaemia vera and vice versa. Br J Haematol 2011; 153:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/24\">",
"      Passamonti F, Rumi E, Caramella M, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 2008; 111:3383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/25\">",
"      Tefferi A, Lasho TL, Schwager SM, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006; 106:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/26\">",
"      Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V&gt;F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 110:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/27\">",
"      Moliterno AR, Williams DM, Rogers O, et al. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol 2008; 36:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/28\">",
"      Alvarez-Larr&aacute;n A, Bellosillo B, Mart&iacute;nez-Avil&eacute;s L, et al. Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. Br J Haematol 2009; 146:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/29\">",
"      Koren-Michowitz M, Landman J, Cohen Y, et al. JAK2V617F allele burden is associated with transformation to myelofibrosis. Leuk Lymphoma 2012; 53:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/30\">",
"      Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005; 105:2664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/31\">",
"      Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005; 105:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/32\">",
"      Passamonti F, Rumi E, Arcaini L, et al. Leukemic transformation of polycythemia vera: a single center study of 23 patients. Cancer 2005; 104:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/33\">",
"      Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood 2008; 112:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/34\">",
"      Bocchia M, Vannucchi AM, Gozzetti A, et al. Insights into JAK2-V617F mutation in CML. Lancet Oncol 2007; 8:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/35\">",
"      Wang X, Tripodi J, Kremyanskaya M, et al. BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia. Blood 2013; 121:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/36\">",
"      Cambier N, Renneville A, Cazaentre T, et al. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 2008; 22:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/37\">",
"      Hussein K, Bock O, Theophile K, et al. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia 2008; 22:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/38\">",
"      Tefferi A, Solberg LA, Silverstein MN. A clinical update in polycythemia vera and essential thrombocythemia. Am J Med 2000; 109:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/39\">",
"      Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981; 304:441.",
"     </a>",
"    </li>",
"    <li>",
"     Landaw SA. Acute leukemia in polycythemia vera. In: Polycythemia Vera and the Myeloproliferative Disorders, Wasserman LR, Berk PD, Berlin NI (Eds), WB Saunders, Philadelphia 1995. p.154.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/41\">",
"      Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 1986; 23:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/42\">",
"      Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997; 34:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/43\">",
"      Donovan PB, Kaplan ME, Goldberg JD, et al. Treatment of polycythemia vera with hydroxyurea. Am J Hematol 1984; 17:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/44\">",
"      Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997; 90:3370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/45\">",
"      Tatarsky I, Sharon R. Management of polycythemia vera with hydroxyurea. Semin Hematol 1997; 34:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/46\">",
"      West WO. Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period. South Med J 1987; 80:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/47\">",
"      Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol 2003; 74:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/48\">",
"      Kiladjian JJ, Chevret S, Dosquet C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011; 29:3907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/49\">",
"      Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/50\">",
"      Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood 1997; 89:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/51\">",
"      Sterkers Y, Preudhomme C, La&iuml; JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/52\">",
"      Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol 1994; 52:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/53\">",
"      Berlin N, Berlin NI. Polycythemia vera. Hematol Oncol Clin North Am 2003; 17:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/54\">",
"      Hanft VN, Fruchtman SR, Pickens CV, et al. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood 2000; 95:3589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/55\">",
"      Silver RT. Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet 1988; 2:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/56\">",
"      Silver RT. Interferon alfa: effects of long-term treatment for polycythemia vera. Semin Hematol 1997; 34:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/57\">",
"      Elliott MA, Tefferi A. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 1997; 23:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/58\">",
"      Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008; 22:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/59\">",
"      Finelli C, Gugliotta L, Gamberi B, et al. Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa. Am J Hematol 1993; 43:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/60\">",
"      Taylor PC, Dolan G, Ng JP, et al. Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data. Br J Haematol 1996; 92:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/61\">",
"      Quesada JR, Talpaz M, Rios A, et al. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 4:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/62\">",
"      Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011; 117:4706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/63\">",
"      Samuelsson J, Hasselbalch H, Bruserud O, et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 2006; 106:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/64\">",
"      Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 2007; 110:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/65\">",
"      Gowin K, Thapaliya P, Samuelson J, et al. Experience with pegylated interferon &alpha;-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 2012; 97:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/66\">",
"      Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112:3065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/67\">",
"      Quint&aacute;s-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27:5418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/68\">",
"      Gilbert HS. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer 1998; 83:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/69\">",
"      Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 2006; 107:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/70\">",
"      Hino M, Futami E, Okuno S, et al. Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera. Ann Hematol 1993; 66:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/71\">",
"      Messora C, Bensi L, Vecchi A, et al. Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol 1994; 86:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/72\">",
"      Sacchi S, Leoni P, Liberati M, et al. A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera. Ann Hematol 1994; 68:247.",
"     </a>",
"    </li>",
"    <li>",
"     NCT 01259856 file://clinicaltrials.gov/ct2/show/study/NCT01259856?term=polycythemia+vera+hydroxyurea&amp;rank=2&amp;show_locs=Y#locn (Accessed on October 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/74\">",
"      Thomas DJ, du Boulay GH, Marshall J, et al. Cerebral blood-flow in polycythaemia. Lancet 1977; 2:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/75\">",
"      Wasserman LR, Balcerzak SP, Berk PD, et al. Influence of therapy on causes of death in polycythemia vera. Trans Assoc Am Physicians 1981; 94:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/76\">",
"      Di Nisio M, Barbui T, Di Gennaro L, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol 2007; 136:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/77\">",
"      Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013; 368:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/78\">",
"      Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood 2007; 109:5104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/79\">",
"      Tefferi A, Spivak JL. Polycythemia vera: scientific advances and current practice. Semin Hematol 2005; 42:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/80\">",
"      Spivak JL. Polycythemia vera, the hematocrit, and blood-volume physiology. N Engl J Med 2013; 368:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/81\">",
"      Oertel MD. Anagrelide, a selective thrombocytopenic agent. Am J Health Syst Pharm 1998; 55:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/82\">",
"      Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group. Am J Med 1992; 92:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/83\">",
"      Landolfi R, Ciabattoni G, Patrignani P, et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992; 80:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/84\">",
"      Patrono C, Rocca B, De Stefano V. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood 2013; 121:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/85\">",
"      Low-dose aspirin in polycythaemia vera: a pilot study. Gruppo Italiano Studio Policitemia (GISP). Br J Haematol 1997; 97:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/86\">",
"      Landolfi R, Marchioli R. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial. Semin Thromb Hemost 1997; 23:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/87\">",
"      Spivak J. Daily aspirin--only half the answer. N Engl J Med 2004; 350:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/88\">",
"      Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/89\">",
"      Squizzato A, Romualdi E, Middeldorp S. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database Syst Rev 2008; :CD006503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/90\">",
"      Jones CM, Dickinson TM. Polycythemia vera responds to imatinib mesylate. Am J Med Sci 2003; 325:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/91\">",
"      Silver RT. Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate. Curr Hematol Rep 2005; 4:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/92\">",
"      Cortes J, Giles F, O'Brien S, et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 2003; 97:2760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/93\">",
"      Jones AV, Silver RT, Waghorn K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 2006; 107:3339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/94\">",
"      Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/95\">",
"      Streiff MB, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood 2002; 99:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/96\">",
"      Spivak JL. The optimal management of polycythaemia vera. Br J Haematol 2002; 116:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/97\">",
"      Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100:4272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/98\">",
"      Finazzi G. Risk stratification, staging, and treatment of patients with polycythemia vera: Italian and European collaboration on low-dose aspirin in polycythemia data. Semin Thromb Hemost 2006; 32:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/99\">",
"      Finazzi G, Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 2008; 22:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/100\">",
"      Balan KK, Critchley M. Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32--a 15 year review. Br J Radiol 1997; 70:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/101\">",
"      Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 2005; 129:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/102\">",
"      Ruggeri M, Gisslinger H, Tosetto A, et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 2002; 71:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/103\">",
"      De Stefano V, Za T, Rossi E, et al. Recurrent venous thrombosis in patients with polycythemia vera and essential thrombocythemia. Clin Leukemia 2007; 1:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/104\">",
"      Ruggeri M, Rodeghiero F, Tosetto A, et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 2008; 111:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/105\">",
"      Diehn F, Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Haematol 2001; 115:619.",
"     </a>",
"    </li>",
"    <li>",
"     Fruchtman SM, Wasserman LR. Therapeutic recommendations for polycythemia vera. In: Polycythemia Vera and the Myeloproliferative Disorders, WB Saunders, Philadelphia 1995. p.337.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/107\">",
"      Weick JK, Donovan PB, Najean Y, et al. The use of cimetidine for the treatment of pruritus in polycythemia vera. Arch Intern Med 1982; 142:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/108\">",
"      Easton P, Galbraith PR. Cimetidine treatment of pruritus in polycythemia vera. N Engl J Med 1978; 299:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/109\">",
"      Jackson N, Burt D, Crocker J, Boughton B. Skin mast cells in polycythaemia vera: relationship to the pathogenesis and treatment of pruritus. Br J Dermatol 1987; 116:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/110\">",
"      Harrison AR, Littenberg G, Goldstein L, Kaplowitz N. Pruritus, cimetidine, and polycythemia. N Engl J Med 1979; 300:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/111\">",
"      Baldo A, Sammarco E, Martinelli V, et al. UVB phototherapy for pruritus in polycythaemia vera. J Dermatol Treat 1996; 7:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/112\">",
"      Jeanmougin M, Rain JD, Najean Y. Efficacy of photochemotherapy on severe pruritus in polycythemia vera. Ann Hematol 1996; 73:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/113\">",
"      Kolodny L, Horstman LL, Sevin BU, et al. Danazol relieves refractory pruritus associated with myeloproliferative disorders and other diseases. Am J Hematol 1996; 51:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/114\">",
"      Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood 2002; 99:2627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/115\">",
"      Michiels JJ. Erythromelalgia and vascular complications in polycythemia vera. Semin Thromb Hemost 1997; 23:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/116\">",
"      van Genderen PJ, Michiels JJ. Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 1997; 23:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/117\">",
"      McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005; 130:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/56/28554/abstract/118\">",
"      Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010; 116:3735.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4534 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-BE0BA8F269-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_56_28554=[""].join("\n");
var outline_f27_56_28554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Thrombotic events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hematologic complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Acute leukemia/MDS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16722283\">",
"      - Chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      THERAPEUTIC TRIALS IN PV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      The major PVSG trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Secondary malignancies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Post-PV myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Conclusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Subsequent PVSG protocols",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Phlebotomy plus aspirin and dipyridamole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hydroxyurea versus pipobroman",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Interferon alpha",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Pegylated interferon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8323402\">",
"      The optimal hematocrit in PV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Anagrelide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Low-dose aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Imatinib mesylate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8180693\">",
"      Response to treatment with hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Acquired von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pruritus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Erythromelalgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16772936\">",
"      Transformation to myelodysplasia or acute leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7838225\">",
"      Prognosis and need for treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7838342\">",
"      Overall treatment goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7839177\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7839163\">",
"      Development of myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7839170\">",
"      Development of myelodysplasia or acute leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4534\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4534|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/16/24835\" title=\"figure 1\">",
"      Organiz heme malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34365\" title=\"figure 2\">",
"      PVSG survival after 7 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/37/41565\" title=\"figure 3\">",
"      PVSG thrombosis-free survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/47/42749\" title=\"figure 4\">",
"      PVSG malignancy-free survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4534|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/25/17808\" title=\"picture 1\">",
"      Erythromelalgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4534|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/0/39947\" title=\"table 1\">",
"      Properties of hydroxyurea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=related_link\">",
"      Asymptomatic hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=related_link\">",
"      Classification and pathophysiology of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=related_link\">",
"      Clinical manifestations and diagnosis of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=related_link\">",
"      Diagnosis and clinical manifestations of essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24777?source=related_link\">",
"      Diagnostic approach to the patient with polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=related_link\">",
"      Diagnostic approach to the patient with suspected polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=related_link\">",
"      Overview of the treatment of myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/14/12513?source=related_link\">",
"      Patient information: Polycythemia vera (PV) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=related_link\">",
"      Prevention of recurrent gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32202?source=related_link\">",
"      Prognosis and treatment of essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36922?source=related_link\">",
"      Prognosis and treatment of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/24/17800?source=related_link\">",
"      Treatment of acute gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=related_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_56_28555="WHO classification anal cancer";
var content_f27_56_28555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    WHO classification of anal cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Anal canal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Squamous cell (cloacogenic) carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Large cell keratinizing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Large cell nonkeratinizing (transitional)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Basaloid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Adenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Rectal type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Of anal glands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Within anorectal fistula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Undifferentiated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Anal margin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Squamous cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Giant condyloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Basal cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bowen's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paget's disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_56_28555=[""].join("\n");
var outline_f27_56_28555=null;
var title_f27_56_28556="POP recurrence risk";
var content_f27_56_28556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for recurrent pelvic organ prolapse",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk factor*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adjusted odds ratio (95% confidence interval)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;60 years",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        3.2 (1.6-6.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;60 years",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        4.1 (1.6-10.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;73 years",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        6.3 (2.3-17.5)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Preoperative pelvic organ prolapse stage (POP-Q)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stage 3 or 4",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        2.7 (1.3-5.3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stage 3 or 4",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        3.9 (1.2-13.0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stage 4",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        5.6 (1.1-29.3)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Body Mass Index &gt;26 kg/m",
"         <sup>",
"          2",
"         </sup>",
"         <sup>",
"          [3]",
"         </sup>",
"        </strong>",
"       </td>",
"       <td>",
"        2.9 (1.1-6.7)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Body weight &gt;65 kg",
"         <sup>",
"          [2]",
"         </sup>",
"        </strong>",
"       </td>",
"       <td>",
"        4.0 (1.6-9.6)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The comparator for each risk factor group is the group of women with pelvic organ prolapse that are not included in the specified group (eg, the comparator for &gt;60 years is &le;60 years OR for stage 4 is stage 1, 2, or 3).",
"     <br/>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Whiteside, JL, Weber, AM, Meyn, LA, Walters, MD. Risk factors for prolapse recurrence after vaginal repair. Am J Obstet Gynecol 2004; 191:1533-8.",
"       </li>",
"       <li>",
"        Diez-Itza, I, Aizpitarte, I, Becerro, A. Risk factors for the recurrence of pelvic organ prolapse after vaginal surgery: A review at 5 years after surgery. International Urogynecology Journal 2007; 18:1317-24.",
"       </li>",
"       <li>",
"        Nieminen, K, Huhtala, H, Heinonen, PK. Anatomic and functional assessment and risk factors of recurrent prolapse after vaginal sacrospinous fixation. Acta Obstetricia Et Gynecologica Scandinavica 2003; 82:471-8.",
"       </li>",
"       <li>",
"        Jeon, MJ, Chung, SM, Jung, HJ, Kim, SK, Bai, SW. Risk factors for the recurrence of pelvic organ prolapse. Gynecologic &amp; Obstetric Investigation 2008; 66:268-73.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_56_28556=[""].join("\n");
var outline_f27_56_28556=null;
var title_f27_56_28557="Progn strat adv HCC";
var content_f27_56_28557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prognostic stratifications for advanced hepatocellular carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"3\">",
"       Multivariate Cox model and the points assigned to each category of prognostic factors in the new prognostic score system",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Characteristics",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       Point",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"3\">",
"       Patient characteristics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" rowspan=\"2\">",
"       Ascites",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" rowspan=\"2\">",
"       Abdominal pain",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" rowspan=\"2\">",
"       Weight loss",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" rowspan=\"3\">",
"       Child-Pugh grade",
"      </td>",
"      <td>",
"       C",
"      </td>",
"      <td>",
"       5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       B",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"3\">",
"       Biochemistry",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" rowspan=\"2\">",
"       Serum alkaline phosphatase (ALP), int. unit/L",
"      </td>",
"      <td>",
"       &gt;200",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &le;200",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" rowspan=\"3\">",
"       Total bilirubin",
"      </td>",
"      <td>",
"       &gt;50 int. unit/L (2.9 mg/dL)",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &gt;33 - &le;50 int. unit/l (1.9 mg/dL - 2.9 mg/dL)",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &le;33 int unit/L (1.9 mg/dL)",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" rowspan=\"2\">",
"       Urea",
"      </td>",
"      <td>",
"       &gt;8.9 mmol/L (&gt;25 mg/dL)",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &le;8.9 mmol/L (&le;25 mg/dL)",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"3\">",
"       Tumor characteristics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" rowspan=\"2\">",
"       Portal vein thrombosis",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" rowspan=\"3\">",
"       Tumor size",
"      </td>",
"      <td>",
"       Diffuse",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &gt;5 cm",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &le;5 cm",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" rowspan=\"2\">",
"       Lung metastases",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" rowspan=\"2\">",
"       Serum alpha-fetoprotein (AFP), ng/mL",
"      </td>",
"      <td>",
"       &gt;400",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &le;400",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"3\">",
"       Probability of patients surviving at least 3 months estimated by the advanced liver cancer prognostic system score",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Prognosis",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       Score",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       3-month survival rate, %",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Good",
"      </td>",
"      <td>",
"       0-2",
"      </td>",
"      <td>",
"       &gt;81",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3-6",
"      </td>",
"      <td>",
"       72-80",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7-8",
"      </td>",
"      <td>",
"       66-69",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Intermediate",
"      </td>",
"      <td>",
"       9",
"      </td>",
"      <td>",
"       63",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10-12",
"      </td>",
"      <td>",
"       51-59",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       13-14",
"      </td>",
"      <td>",
"       42-47",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       38",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Poor",
"      </td>",
"      <td>",
"       16",
"      </td>",
"      <td>",
"       33",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       17-19",
"      </td>",
"      <td>",
"       21-29",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       20-22",
"      </td>",
"      <td>",
"       10-17",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &ge;23",
"      </td>",
"      <td>",
"       &lt;10",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     int. unit: international unit.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yau T, Yao TJ, Chan P, et al. A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials. Cancer 2008; 113:2742. Copyright &copy; 2008 John Wiley &amp; Sons, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_56_28557=[""].join("\n");
var outline_f27_56_28557=null;
var title_f27_56_28558="Drugs interact theophylline I";
var content_f27_56_28558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65611%7EPULM%2F78641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65611%7EPULM%2F78641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinically significant drug interactions with theophylline",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type of interaction",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect on theophylline serum",
"concentrations or pharmacologic effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenosine",
"       </td>",
"       <td>",
"        Theophylline blocks adenosine receptors",
"       </td>",
"       <td>",
"        Higher doses of adenosine may be required to achieve",
"desired anti-arrhythmic effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol",
"       </td>",
"       <td>",
"        A single large dose of alcohol (3 ml/kg of whiskey)",
"decreases theophylline clearance for up to 24 hours",
"       </td>",
"       <td>",
"        33 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allopurinol",
"       </td>",
"       <td>",
"        Decreases theophylline clearance at allopurinol doses &ge;600 mg/day",
"       </td>",
"       <td>",
"        25 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aminoglutethimide",
"       </td>",
"       <td>",
"        Increases theophylline clearance by induction of",
"microsomal enzyme activity",
"       </td>",
"       <td>",
"        25 percent decrease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine",
"       </td>",
"       <td>",
"        Similar to aminoglutethimide",
"       </td>",
"       <td>",
"        30 percent decrease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cimetidine",
"       </td>",
"       <td>",
"        Decreases theophylline clearance by inhibiting",
"cytochrome P450 1A2",
"       </td>",
"       <td>",
"        70 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciprofloxacin",
"       </td>",
"       <td>",
"        Similar to cimetidine",
"       </td>",
"       <td>",
"        40 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clarithromycin",
"       </td>",
"       <td>",
"        Similar to erythromycin",
"       </td>",
"       <td>",
"        25 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Diazepam",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Benzodiazepines increase CNS concentrations of",
"adenosine, a potent CNS depressant, while theophylline blocks adenosine",
"receptors",
"       </td>",
"       <td>",
"        Larger diazepam doses may be required to produce",
"desired level of sedation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discontinuation of theophylline without reduction of",
"diazepam dose may result in respiratory depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disulfiram",
"       </td>",
"       <td>",
"        Decreases theophylline clearance by inhibiting",
"hydroxylation and demethylation",
"       </td>",
"       <td>",
"        50 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enoxacin",
"       </td>",
"       <td>",
"        Similar to cimetidine",
"       </td>",
"       <td>",
"        300 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ephedrine",
"       </td>",
"       <td>",
"        Synergistic CNS effects",
"       </td>",
"       <td>",
"        Increased frequency of nausea, nervousness, and insomnia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythromycin",
"       </td>",
"       <td>",
"        Erythromycin metabolite decreases theophylline",
"clearance by inhibiting cytochrome P450 3A3",
"       </td>",
"       <td>",
"        35 percent increase. Erythromycin steady-state serum",
"concentrations decrease by a similar amount",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Estrogen",
"       </td>",
"       <td>",
"        Estrogen-containing oral contraceptives decrease",
"theophylline clearance in a dose-dependent fashion. The effect of",
"progesterone on theophylline clearance is unknown",
"       </td>",
"       <td>",
"        30 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flurazepam",
"       </td>",
"       <td>",
"        Similar to diazepam",
"       </td>",
"       <td>",
"        Similar to diazepam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluvoxamine",
"       </td>",
"       <td>",
"        Similar to cimetidine",
"       </td>",
"       <td>",
"        Similar to cimetidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Halothane",
"       </td>",
"       <td>",
"        Halothane sensitizes the myocardium to catecholamines;",
"theophylline increases release of endogenous catecholamines",
"       </td>",
"       <td>",
"        Increased risk of",
"ventricular arrhythmias",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Hendeles, L, Jenkins, J, Temple, R, Pharmacotherapy 1995; 15:409.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinically significant drug interactions with theophylline",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type of interaction",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect on theophylline serum",
"concentrations or pharmacologic effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interferon, human recombinant alpha-A",
"       </td>",
"       <td>",
"        Decreases theophylline clearance",
"       </td>",
"       <td>",
"        100 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isoproterenol (IV)",
"       </td>",
"       <td>",
"        Increases theophylline clearance",
"       </td>",
"       <td>",
"        20 percent decrease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ketamine",
"       </td>",
"       <td>",
"        Pharmacologic",
"       </td>",
"       <td>",
"        May lower theophylline seizure threshold",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lithium",
"       </td>",
"       <td>",
"        Theophylline increases lithium renal clearance",
"       </td>",
"       <td>",
"        Lithium dose required to achieve a therapeutic serum",
"concentration increased an average of 60 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lorazepam",
"       </td>",
"       <td>",
"        Similar to diazepam",
"       </td>",
"       <td>",
"        Similar to diazepam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methotrexate (MTX)",
"       </td>",
"       <td>",
"        Decreases theophylline clearance",
"       </td>",
"       <td>",
"        20 percent increase after low-dose MTX, higher dose MTX",
"may have a greater effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mexiletine",
"       </td>",
"       <td>",
"        Similar to disulfiram",
"       </td>",
"       <td>",
"        80 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Midazolam",
"       </td>",
"       <td>",
"        Similar to diazepam",
"       </td>",
"       <td>",
"        Similar to diazepam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moricizine",
"       </td>",
"       <td>",
"        Increases theophylline clearance",
"       </td>",
"       <td>",
"        25 percent decrease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancuronium",
"       </td>",
"       <td>",
"        Theophylline may antagonize non-depolarizing",
"neuromuscular blocking effects; possibly due to phosphodiesterase",
"inhibition",
"       </td>",
"       <td>",
"        Larger dose of pancuronium may be required to achieve",
"neuromuscular blockade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pentoxifylline",
"       </td>",
"       <td>",
"        Decreases theophylline clearance",
"       </td>",
"       <td>",
"        30 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenobarbital (PB)",
"       </td>",
"       <td>",
"        Similar to aminoglutethimide",
"       </td>",
"       <td>",
"        25 percent decrease after more than two weeks of",
"concurrent PB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Phenytoin",
"       </td>",
"       <td>",
"        Phenytoin increases theophylline clearance by",
"increasing microsomal enzyme activity",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Serum theophylline and phenytoin concentrations",
"decrease about 40 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Theophylline decreases phenytoin absorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propafenone",
"       </td>",
"       <td>",
"        Decreases theophylline clearance and pharmacologic",
"interaction",
"       </td>",
"       <td>",
"        40 percent increase. Beta-2-blocking effect may",
"decrease efficacy of theophylline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propranolol",
"       </td>",
"       <td>",
"        Similar to cimetidine and pharmacologic interaction",
"       </td>",
"       <td>",
"        100 percent increase. Beta-2-blocking effect may",
"decrease efficacy of theophylline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampin",
"       </td>",
"       <td>",
"        Increases theophylline clearance by increasing",
"cytochrome P450 1A2 and 3A3 activity",
"       </td>",
"       <td>",
"        20 to 40 percent decrease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfinpyrazone",
"       </td>",
"       <td>",
"        Increases theophylline clearance by increasing",
"demethylation and hydroxylation. Decreases renal clearance of",
"theophylline",
"       </td>",
"       <td>",
"        20 percent decrease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tacrine",
"       </td>",
"       <td>",
"        Similar to cimetidine, also increases renal clearance",
"of theophylline",
"       </td>",
"       <td>",
"        90 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thiabendazole",
"       </td>",
"       <td>",
"        Decreases theophylline clearance",
"       </td>",
"       <td>",
"        190 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ticlopidine",
"       </td>",
"       <td>",
"        Decreases theophylline clearance",
"       </td>",
"       <td>",
"        60 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Troleandomycin",
"       </td>",
"       <td>",
"        Similar to erythromycin",
"       </td>",
"       <td>",
"        33 to 100 percent increase depending on troleandomycin",
"dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Verapamil",
"       </td>",
"       <td>",
"        Similar to disulfiram",
"       </td>",
"       <td>",
"        20 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zafirlukast",
"       </td>",
"       <td>",
"        Mechanism not studied; theophylline decreases either",
"bioavailability or",
"clearance of zafirlukast. Zafirlukast has no effect on theophylline",
"clearance",
"       </td>",
"       <td>",
"        Zafirlukast blood levels decrease an average of 40",
"percent, which is likely to render it ineffective",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zileuton",
"       </td>",
"       <td>",
"        Zileuton inhibits cytochrome P-450 1A2 and, thus,",
"decreases theophylline clearance",
"       </td>",
"       <td>",
"        100 percent increase",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Hendeles, L, Jenkins, J, Temple, R, Pharmacotherapy 1995; 15:409.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_56_28558=[""].join("\n");
var outline_f27_56_28558=null;
var title_f27_56_28559="Central line catheter wire";
var content_f27_56_28559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Central venous catheter being threaded onto guidewire",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_56_28559=[""].join("\n");
var outline_f27_56_28559=null;
